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Narcotic analgesics produce pain relief generally through activation of µ opioid 
receptors (MOR), but the use of these analgesics is limited by their side effects, 
namely respiratory depression, tolerance, physical dependence and constipation. 
Understanding receptor-ligand interactions at the molecular level could facilitate the 
design of novel opioid ligands potentially with less deleterious side effects. This task 
is challenging since there is no crystal structure available for opioid receptors.  
With the aim of understanding MOR-ligand interactions, we designed novel MOR 
selective peptide ligands containing a reactive affinity label group. Affinity labels that 
interact with the receptor in a non-equilibrium manner can provide information about 
specific receptor-ligand interactions. We selected two MOR selective peptides: 
dermorphin, an endogenous ligand present in South American frog skin, and the 
synthetic enkephalin analog DAMGO ([D-Ala2,NMePhe4,glyol]enkephalin), for 
developing electrophilic affinity label derivatives. We substituted D-Orn or D-Lys in 
position 2 (in place of D-Ala) in both dermorphin and DAMGO, and attached a 
bromoacetamide or an isothiocyanate group as the electrophilic functionality to the 
side chain amines of the D-amino acids.  
For the dermorphin derivatives, we successfully identified several affinity labels with 
high MOR affinity (IC50 = 0.1-5 nM) and high selectivity for MOR that exhibit wash-
resistant inhibition of binding to these receptors. Among these, [D-
 2
Lys(=C=S)2]dermorphin was further modified to include a purification tag (d-
desthiobiotin) and a fluorescent tag (Oregon Green or 5-carboxyrhodamine B). This 
multifunctional affinity label peptide was synthesized successfully using an Fmoc-
solid phase synthetic strategy. Initial fluorescent microscopy studies suggest 
irreversible labeling of MOR expressed on SH-SY5Y cells by this multifunctional 
peptide, thus demonstrating the utility of the fluorescent tag.  
For the DAMGO series of analogs, the bromoacetamide derivatives exhibited 
subnanomolar binding affinity (IC50 = 0.45 nM) to MOR. However, the 
isothiocyanate derivatives resulted in the formation of an unexpected cyclic O-alkyl 
thiocarbamate side product. This side reaction was successfully overcome by 
replacing the glyol in DAMGO by the glycylamide, yielding affinity label derivatives 
that exhibited subnanomolar affinity (IC50 = 0.3-0.8 nM) and wash-resistant 
inhibition of MOR binding. 
These high affinity peptide-based affinity labels will be useful pharmacological tools 



































1.1 Background and Significance 
 
      Narcotic analgesics such as morphine produce pain relief mainly through 
activation of µ opioid receptors (MOR) which belong to the family of G-protein 
coupled receptors (GPCR).1 However a plethora of side effects associated with the 
clinically used analgesics acting at MOR, such as respiratory depression, 
constipation, tolerance and physical dependence limit their therapeutic use.1-3 
Therefore, there is an urgent need to develop potent analgesics devoid of these severe 
side effects. To achieve this goal, it is of utmost importance to study the interactions 
of MOR selective ligands with their receptor at the molecular level.  
      Since the cloning of the opioid receptors in the 1990s and subsequent 
determination of their sequences,4-8 considerable advancements have been made in 
understanding receptor-ligand interactions at the molecular level. Information 
obtained from chimeric opioid receptors and receptors containing point mutations has 
demonstrated the complexities of ligand-receptor interactions, including differences 
in interactions of the same ligands with different receptors, and of different ligands 
with the same receptor.9 Through such studies, it was also found that the opioid 
peptides and alkaloids use common sites for binding, but their modes of interaction 
are different.9-13 Information has also been obtained on the roles of individual 
residues in opioid receptors from site-directed mutagenesis.9 For example, results 
from the mutation of Asp in transmembrane (TM) 2 suggested that agonists and 
antagonists may bind differently to this residue.14, 15  
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      In the absence of crystal structures of opioid receptors, computational models of 
these receptors remain an important tool for understanding structure-function 
relationships for these receptors.16 Homology modeling of opioid receptors based on 
the existing crystal structures of rhodopsin17, 18 is the most common approach and 
several groups have reported computational models of opioid receptors based on 
homology modeling.19-23 Several reports have emerged on computational models of 
nonpeptide ligands binding to their receptors.24-31 The rigid structures of some of 
these ligands make the docking studies less complicated. However, the flexible nature 
of opioid peptides makes the computational modeling of such ligands bound to their 
receptor quite challenging, and therefore reports for these compounds in the literature 
have been limited. There is only one example of a MOR selective peptide agonist (the 
tetrapeptide JOM6)32 whose computational model has been developed using 
structural constraints.33, 34 Comparisons of models of agonist-bound MOR with MOR 
in an inactive state33 suggested that rotation of the side chain of Trp293 in TM6 is a 
major change that takes place upon agonist binding to MOR. However, a serious 
limitation of such homology modeling is the lack of identity between opioid receptor 
sequences and rhodopsin (only ~20% identity for all residues and ~29% identity in 
the TM regions). Therefore, homology modeling of rhodopsin and opioid receptors 
may generate many errors, mostly from misalignment of sequences.35-37 
      Although information obtained from both molecular biology techniques and 
computational models has provided tremendous insight into the complexities of 
opioid receptor-ligand interactions, these techniques suffer from potential drawbacks. 
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Changes in the primary sequence of receptors by site-directed mutagenesis or in 
chimeric receptors can affect protein secondary and / or tertiary structure, and in turn 
affect the interactions and affinities of various ligands for such receptors.9 The use of 
computational models of opioid receptors have inherent drawbacks associated with 
the low sequence homology between the template and the protein being modeled, and 
additional receptor specific and ligand specific experimental constraints are needed to 
improve the accuracy of such models.9 From the above discussion it is evident that 
there is a need to develop more direct methods to identify specific receptor-ligand 
interactions for opioid receptors. 
      Affinity labels, which are compounds that interact with their receptors in an 
irreversible, two-step recognition process,38 can provide direct information on 
receptor-ligand interactions. The first step is the reversible binding of the affinity 
label to the receptor, followed by covalent attachment of the affinity label to the 
receptor, provided that the affinity label has sufficient reactivity and is properly 
oriented to react with an appropriate functionality on the receptor.38 By identifying 
the attachment point of an affinity label to its receptor, direct evidence can be 
obtained on specific receptor-ligand interactions. Such information can then be used 
as an ‘anchor point’ to assess and improve existing computational models. This 
concept forms the central hypothesis of this research. 
      The objective of this research is to develop peptide-based electrophilic affinity 
labels selective for MOR. Since MOR is the primary opioid receptor targeted to 
modulate pain, it is of utmost importance to understand the molecular interactions of 
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MOR-selective ligands at the molecular level. Since irreversible binding of an 
electrophilic affinity label depends on the reactivity of the label as well as the 
proximity of a nearby nucleophile in the receptor, an increase in specificity can be 
achieved by using such labels.38 We chose to design peptide-based affinity labels for 
two reasons. First, there is considerable evidence in the literature, based on site-
directed mutagenesis of opioid receptors, suggesting different modes of binding for 
peptide vs nonpeptide ligands to opioid receptors.9-13  Since endogenous ligands for 
opioid receptors are peptides, it is important to explore the interactions of such 
peptides with their receptors and also understand the differences in their binding to 
receptors compared to nonpeptide ligands. Examples of peptide ligands with high 
affinity for MOR are the enkephalins, β-endorphin1 and the recently identified 
endomorphins39 the mammalian peptides and dermorphin, the only example of an 
endogenous MOR selective opioid peptide found in amphibian skin.40 Furthermore, 
complimentary information can be obtained from studying interactions of peptides 
and nonpeptides with opioid receptors, and this information can be utilized in 
developing novel drugs targeting opioid receptors. Secondly, peptide-based affinity 
labels offer unique advantages over nonpeptide ligands. The polymeric nature of 
peptides permits easy incorporation of additional functionalities (e.g. biotin and / or a 
fluorescent group) which can aid in receptor isolation and characterization. 
      There have been very few reports of electrophilic peptide-based affinity labels 
selective for MOR. The only reported examples of such compounds are DAMK ([D- 
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Ala2,NMePhe4]enkephalin-1-4 chloromethyl ketone)41 and [D-
Ala2,Leu(CH2S)Npys5]-enkephalin (where Npys is 3-nitro-2-pyridinesulphenyl).42 
Previous attempts in our research group to prepare affinity labels for MOR by 
incorporating an electrophilic functionality such as a bromoacetamide or an 
isothiocyanate on the para position of either Phe3 or Phe4 of endomorphin-2 (Tyr-Pro-
Phe-PheNH2) were unsuccessful because the modified analogs exhibited large (40- to 
80-fold) decreases in MOR binding affinity compared to endomorphin-2.43 
      The goal of the present research was to design, synthesize and evaluate 
electrophilic affinity labels selective for MOR. Two MOR selective ligands were 
chosen for further modification: dermorphin, and DAMGO, a synthetic analog of 
enkephalin.44 
1.2 Research Projects 
1.2.1 Project 1 
Discovery of Dermorphin-Based Affinity Labels with Subnanomolar Affinity for 
Mu Opioid Receptors (Chapter 3) 
The objective of this project was to design, synthesize and evaluate the binding 
affinity of peptide-based electrophilic affinity labels for MOR based on dermorphin, 
an endogenous heptapeptide present in South American frog skin45 exhibiting 
exceptionally high affinity (IC50 = 0.72 nM) and selectivity (250-fold) for MOR over 
DOR. 
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      Previously, the para position of Phe3 or a Phe in position 5 of dermorphin and 
[Lys7]dermorphin, was modified by introducing an electrophilic functionality such as 
a bromoacetamide or isothiocyanate group.46 Modification of the ‘message’ domain 
(Phe3) resulted in >1000-fold decrease in MOR affinity. Introduction of a Phe residue 
in position 5 of dermorphin and [Lys7]dermorphin was well tolerated and the peptides 
retained nanomolar affinity for MOR, but the analogs containing the affinity label 
group did not exhibit wash-resistant inhibition of binding to MOR, as would be 
expected for an affinity label.46 
      In the present study we chose an alternative location in the ‘message’ sequence, 
position 2, to incorporate a reactive functionality. Larger D-amino acids are tolerated 
at this position in peptides by MOR,45 suggesting that introduction of an affinity label 
into the side chain of this residue would not interfere with the binding of these ligands 
to the receptor. In the present study, D-Ala at position 2 was replaced by D-Orn or D-
Lys. The free amine on the side chain of these amino acids was used as a suitable 
handle to incorporate the electrophilic bromoacetamide or isothiocyanate 
functionalities (Figure 1.1). This strategy also permitted varying the length of the 
amino acid side chain to optimize binding of the affinity label to its receptor. For 
these series of analogs, [D-Orn(COCH3)2]- and [D-Lys(COCH3)2]dermorphin served 








Figure 1.1. Design of potential affinity labels for MOR and the corresponding reversible control 
peptides based on the parent peptide dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-SerNH2). 
 
 
The new series of analogs were successfully synthesized following a solid-phase 
synthesis procedure. From the pharmacological assays, high affinity ligands were 
identified that exhibited wash-resistant inhibition of binding to MOR.47 
1.2.2 Project 2 
Synthesis and Evaluation of DAMGO-Based Affinity Labels for MOR and 
Discovery of an Unexpected Side Reaction (Chapter 4) 
     Continuing our effort to design new, selective and potent peptide-based affinity 
labels for MOR, we chose DAMGO, a highly potent and selective agonist for MOR,44 
as a parent ligand for further modification. Based on the successful design of 
dermorphin-based affinity label by substituting D-Orn or D-Lys in position 2 and 
attaching an electrophilic functionality, i.e. an isothiocyanate or a bromoacetamide, 




Figure 1.2. Potential affinity labels for MOR and the corresponding reversible control peptides based 
on the parent peptide DAMGO (Tyr-D-Ala-Gly-NMePhe-glyol) 
 
      During the attempted synthesis and purification of the isothiocyanate containing 
analogs of DAMGO an unexpected side reaction occurred resulting in the formation 
of cyclic-O-alkyl thiocarbamate derivatives (Figure 1.3). The identities of the 
products were determined by various techniques: (HPLC, IR, NMR and MS).48 
 
Figure 1.3. Proposed reaction for the formation of the cyclic O-alkyl thiocarbamate. Here [D-
Lys(=C=S)2]DAMGO is shown as the example. 
 
      Based on the pharmacological assays analogs with high binding affinities were 
identified that also exhibited wash resistant inhibition of binding to MOR. 
      The isothiocyanate analogs of [D-Orn2] and [D-Lys2]DAMGO were modified to 
overcome the side reaction. This was achieved by replacing the glyol functionality by 
a glycylamide. Both the bromoacetamide and isothiocyanate affinity labels were 
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synthesized and evaluated in the glycylamide series. The affinity label functionalities 
were well tolerated by MOR, but most of the affinity labels in this series lost 
selectivity for MOR over DOR compared to the corresponding DAMGO analogs. 
1.2.3 Project 3 
Design, Synthesis and Evaluation of a Dermorphin-Based Multifunctional 
Affinity Label Probe for Mu Opioid Receptors (Chapter 5) 
      From the series of new dermorphin-based affinity labels, described in Project 1 
above, we identified [D-Lys(CS)2]dermorphin as the lead peptide for designing a 
multifunctional probe with the long range goal of identifying the attachment point of 
this peptide to MOR. This ligand was selected due to its high affinity (IC50 = 0.38 
nM), selectivity for MOR over DOR (255-fold) and wash-resistant inhibition of 
binding to MOR. Peptides, due to their polymeric nature, provide definite advantages 
over nonpeptides in receptor isolation studies. For example additional residues can be 
incorporated which can bear a purification tag such as biotin or d-desthiobiotin. Such 
a tag enables receptor enrichment via affinity purification with a streptavidin-based 
extraction procedure.49-51 Opioid receptors are membrane proteins that are expressed 
at very low concentrations in different cell lines.51 Therefore affinity purification via 
d-desthiobiotin-streptavidin interaction would enrich the available receptor. 
Additionally, a fluorescent label could also be incorporated to facilitate the detection 
of labeled receptors. In this project, Oregon Green or 5-carboxyrhodamine was used 
as the fluorophore. Figure 1.4 shows the design of the multifunctional affinity label 
probe for MOR. 
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Figure 1.4. Design of the dermorphin-based multifunctional affinity labels for MOR 
 
      The affinity label derivative [D-Lys(CS)2]dermorphin was extended at the C-
terminus by incorporation of two Lys residues, separated from each other and the 
peptide by hydrophilic poly(ethylene glycol) (PEG)-like linkers to decrease 
hydrophobicity of the peptides and minimize non-specific binding. The functional 
tags, d-desthiobiotin for purification and either Oregon Green or 5-carboxyrhodamine 
B as fluorescent labels, were attached to the side chains of the additional Lys 
residues. Solid-phase synthetic methodology was developed to selectively incorporate 
each functionality (the purification tag, fluorescent label and the affinity label) 
sequentially without any interference from the other side chain functionalities in the 
peptide. A C-terminal β-alanine was incorporated in order to facilitate introduction of 
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the bulky fluorescent group to the resin-bound peptide during the synthesis. The [D-
Lys(CS)2]dermorphin-based multilabeled peptides containing either Oregon Green or 
5-carboxyrhodamine B, along with the reversible controls, were successfully 
synthesized following this methodology. Preliminary microscopy experiments 
examining the interaction of the fluorescent affinity label peptide containing Oregon 
Green with MOR on SH-SY5Y cells suggest wash-resistant binding of the 
multifunctional affinity label dermorphin derivative, thus demonstrating the utility of 
this approach.  
1.3 Conclusions 
      The peptide-based affinity labels with high MOR affinity described in this thesis 
will be useful pharmacological tools to study MOR and will aid in understanding 
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Literature Review 
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2.1 Opioid Receptors  
 
      The opioid system modulates a variety of complex physiological functions 
including analgesia, stress response, immunity, neuroendocrine function and 
cardiovascular control. This wide spectrum of neurobiological effects by the opioid 
system is mediated by activation of specific membrane bound receptors.1 
      The term ‘opioid’ is derived from opium from which morphine, the prototypical 
opioid analgesic, was isolated. Although the analgesic effects of opium were known 
for thousands of years, opioid binding sites were first proposed by Beckett et al. only 
in the early 1950s,2 followed by Portoghese et al. in the 1960s3 and Martin et al. in 
1970s.4 The stereospecific binding of opiates to specific receptors in mammalian 
brain tissue was first reported around the same time in 1973.5-8 But it took almost two 
and a half decades of extensive pharmacological research since the first discovery of 
opiate binding sites by Beckett et al. to characterize the different types of opioid 
receptors. To date, three different types of opioid receptors have been cloned, the µ 
opioid receptor (MOR: µ for morphine),9 the κ opioid receptor (KOR: κ for 
ketocyclazocine),10 and the δ  opioid receptor (DOR: δ for mouse vas deferens)10. A 
fourth opioid-like orphan receptor has been identified by homology screening which 
is generally referred to as the opioid-receptor-like-1 (ORL-1) receptor, although it 
does not bind the classical opioid receptor ligands.11, 12 There is also considerable 
pharmacological evidence for the existence of opioid receptor subtypes, particularly 
for subtypes of MOR, which may be products of alternative mRNA splicing,13 
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posttranslational modifications of the receptors,  or homo- or hetero- receptor 
dimerization14 of the existing MOR, KOR, DOR and ORL-1 proteins. 
2.1.1 Structure and Function of Opioid Receptors 
      The cloning of the µ, δ and κ opioid receptor genes in the 1990s followed by 
amino acid sequence comparison of the three receptors9, 15-18 and molecular analysis, 
indicate that they belong to the rhodopsin-like family of GPCRs (G-protein coupled 
receptors).19 GPCRs are characterized by seven putative transmembrane (TM) 
regions, an extracellular domain which includes the N-terminus and extracellular 
loops (EL), and the intracellular domain which includes the C-terminus and 
intracellular loops (IL)20 (Figure 2.1). The highest transmembrane sequence 
homology among the three opioid receptors is found in TM2, TM3, and TM7.9, 21 A 
conserved Asp residue is found in both TM2 and TM3; the conserved TM3 Asp 
residue is thought to be essential for interaction with the protonated amine group in 
opioid ligands.22 The intracellular loops possess similar sequences among all three 
opioid receptor types. However, the extracellular loops are less conserved, 
particularly the second and third loops, and the highest structural diversity among 
opioid receptors is found in the N-terminal sequences. A few sites in the opioid 
receptors have been identified for possible post translational modifications. There are 
two possible glycosylation sites within the N-terminal region.  The C-terminus and 
intracellular loop 3 (IL3) contain possible protein kinase C phosphorylation sites, and 
a possible palmitoylation site is found in the C-terminal sequence. Also, conserved 
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Cys residues are found in the first and second extracellular loops which are thought to 
be involved in a disulfide linkage.  
 
                            Figure 2.1.: Serpentine model of MOR23 
 
2.2 Mu Opioid Receptors (MOR) 
      Opioid analgesics (e.g. morphine), produce pain relief mainly through activation 
of MOR and are considered indispensable drugs for the management of pain.24-26 
However, there are severe deleterious side effects associated with opioid analgesics, 
namely respiratory depression, addiction liability and constipation.27, 28 Martin et al. 
in 1976 first differentiated the pharmacological profile of MOR activation vs. KOR in 
vivo using morphine as the prototype agonist.4, 8 Administration of morphine to dogs 
resulted in a myriad of effects, including miosis, hypothermia, bradycardia, and 
analgesia and physical dependence after chronic administration.4 Also, 
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discontinuation of morphine resulted in an abstinence syndrome that could be 
suppressed by morphine but not by ketocyclazocaine. The latter drug has its own 
spectrum of actions, such as pupillary constriction, sedation and depression of flexor 
reflexes, which Martin attributed to activation of a separate type of receptors now 
referred to as KOR. These studies established the existence of different opioid 
receptor types.4, 8 
      Based on radioligand binding experiments in brains of several species, the 
proportion of MOR is found to be 41% of the opioid receptor population in rat, 25% 
in guinea pig and 25% in the mouse.29 A more precise and direct method to 
characterize regional differences in receptor distribution is autoradiography.30 The 
most common radioligands used for autoradiography studies for MOR are 
[3H]DAMGO ([D-Ala2,MePhe4,glyol]enkephalin)31-33 and [3H]CTOP(D-Phe-
cyclo[Cys-Tyr-D-Trp-Orn-Thr-Pen]-Thr-NH2).34 Based on autoradiographic studies 
of MOR in rat brain, the highest densities are found in the striatum, the accessory 
olfactory bulb, and several areas of thalamic nuclei; in contrast, lower levels of MOR 
were found in the cerebral cortex and cerebellum.35 
     The cloning of the MOR from rat brain was first reported by Chen et al. and 
Fukuda et al. in 19939, 18 and showed 64% homology in amino acid sequences to the 
DOR cloned earlier by Evans et al. and Keiffer et al.15, 16 The expected high affinity 
for selective MOR ligands such as morphine and DAMGO and likewise low affinity 
for DOR the KOR selective ligands were observed for cloned MOR expressed on 
COS-7 cells. 36 
 27
2.2.1 Mutagenesis Studies of MOR 
      Since the cloning of the opioid receptors in 1990s, numerous efforts have been 
undertaken to investigate and identify the molecular basis of ligand recognition and 
selectivity for particular opioid receptor types. Generally, two approaches have been 
utilized to analyze receptor structures. The first approach is to design receptor 
chimeras where domains of one opioid receptor type have been replaced by the 
corresponding domain from a different opioid receptor.22, 37 The other approach 
involves site-directed mutagenesis of critical amino acid residues of a specific 
receptor type to investigate the effect of such changes on ligand binding to the 
receptor.38, 39 Although both of these approaches have been widely used in examining 
the domains of receptors involved in binding, these techniques suffer from the 
drawback of potential alteration of the three dimensional structure of the ligand 
binding region by the structural changes in primary sequences.22 Nevertheless, these 
techniques have been widely used over the past decade and a plethora of information 
has been obtained with regard to the specific domains of the opioid receptors possibly 
involved in binding and selectivity.   
      Several groups have reported the involvement of extracellular loops in the binding 
through constructing opioid receptor chimeras. Through such studies, it was also 
proposed that the binding sites for the opioid peptides and alkaloids are different. 22, 
40-43  Results obtained from constructing MOR / DOR chimeric receptors revealed the 
importance of extracellular loop 1 (EL1) and TM2 for the binding of MOR selective 
ligands.41 It was also reported that a DOR chimeric receptor which included the EL1 
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from MOR bound the MOR selective peptide DAMGO with high affinity, whereas 
the MOR receptor chimera bearing the EL1 from DOR was resulted in 100-fold lower 
affinity for DAMGO.42 The contribution of Lys108 in EL1 of DOR to ligand 
selectivity was demonstrated replacing Lys108 with Asn in the DOR sequence, which 
enabled binding of the MOR selective ligand dermorphin. However, the EL1 does not 
seem to play a critical role for the binding of MOR selective alkaloids.44 An 
investigation of MOR / KOR chimeric receptors suggested that EL3 was critical for 
the high-affinity binding of DAMGO to MOR.17, 45 Additional studies identified four 
residues (Lys303, Val316, Trp318 and His319) in EL3 of MOR that may be 
important for recognition of DAMGO.43 Also, TM6, TM7, and EL3 were found to be 
important for the selective binding of sufentanil to MOR over KOR.44 The 
importance of EL1 and EL3 was further established with chimeric receptors between 
MOR and angiotensin II receptors. When EL1 and 3 from MOR were substituted with 
the corresponding regions of angiotensin II receptors, there were reductions in opioid 
receptor affinities.46 Separate chimeric receptor studies reported by Varga et al.47 and 
Meng et al.48 it was demonstrated that Lys300 in EL3 of MOR represents a critical 
site for the selectivity of peptidic ligands. In addition to demonstrating the 
involvement of the ELs of MOR in conferring selectivity to peptidic ligands, Seki et 
al. also reported ligand-dependent selectivity. While incorporation of EL3 of MOR 
into a KOR chimera imparted high affinity binding for DAMGO, this result did not 
extend to the MOR-selective agents dermorphin and fentanyl.46 Therefore the 
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molecular basis for ligand affinity and selectivity for different opioid receptors 
remains to be fully elucidated. 
      For high affinity binding to opioid receptors, the presence of protonated nitrogen 
in opioid ligands is required. Therefore, an aspartic or a glutamic acid residue in the 
binding pocket of the opioid receptors would potentially serve as a counter ion for 
ligand binding.22 Conflicting evidence concerning the importance of Asp147 on TM3 
of MOR can be found in the literature. Although binding affinities of peptide agonists 
to MOR was eliminated through mutation of Asp147 to Ala in MOR, this mutation 
did not affect the binding of opioid antagonists diprenorphine and naloxone.22 
Furthermore, mutation of Asp147 to Glu resulted in a decrease in binding for 
DAMGO, but not for morphine.39 Therefore, it is speculated that other acidic 
residues, such as the conserved Asp in TM2, could act as the counter ion in agonist 
binding.22 Other charged amino acid residues, such as His297 of MOR, have also 
been implicated in the binding of opioid ligands. Thus, mutation of His297 of MOR 
to Ala resulted in a several fold loss in [3H]DAMGO binding to MOR.39, 49 
Interestingly, this mutation to MOR instilled partial agonistic properties in classical 
opioid antagonists (e.g. naloxone).50 
      One other useful approach to determine the domains of opioid receptors involved  
in opioid binding is through the study of irreversible ligands. Chen et al. 
demonstrated that β-funaltrexamine (βFNA), a MOR selective antagonist, labeled the 
Lys233 in TM5 (see details in section 2.4.2.1).51, 52 This result supports the proposal 
 30
of ligand binding sequences other than EL1 and EL3 for nonpeptide (opiate) 
antagonists. 41-43, 45  
2.2.2 Computational Studies on MOR 
      Currently, there are no high-resolution crystal structures of any of the opioid 
receptors. The only transmembrane receptor proteins in GPCR family whose crystal 
structure have been solved are rhodopsin in its dark state bound to 11-cis retinal,53, 54 
human β2 adrenergic receptor,55, 56 and recently the crystal structure of rhodopsin in 
its G-protein interacting conformation.54 In the absence of crystal structures, 
computational models of opioid receptors are the other available option for 
developing structure-function relationships.57 Homology modeling of opioid receptors 
based on the crystal structure of rhodopsin is the most common approach, and several 
applications of this approach have been reported in the literature.37, 58-62 Fowler and 
coworkers reported a homology model of the agonist bound receptor state of MOR in 
complex with the MOR selective cyclic peptide JOM6,63 using structural 
constraints.64, 65 Comparison of models of agonist-bound MOR with MOR without a 
ligand64 predicted that the rotation of side chain of Trp293 was the major change that 
takes place upon agonist binding to MOR, resulting in the relocation of the indole 
ring of Trp293 from the interface between TM6 and TM7 to the interface between 
transmembrane domains 3, 5, and 6. These movements of TM domains were 
proposed to form a π stacking interaction with the aromatic ring of Tyr1 of JOM6. 
TM6 movement would then reorient the side chain of Met151, Asp147, Lys233, 
Lys303 and Trp318.64, 65 The importance of Trp293 to the activation of MOR had 
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been previously proposed by other groups based on mutagenesis data on rhodopsin 
and agonist-activated leukotriene receptors.66, 67  
       The homology model and molecular dynamics simulation of MOR in 
phospholipids bilayer-aqueous environment was subsequently reported by Zhang et 
al. where they demonstrated the conformational changes observed in TMs as well as 
EL and IL regions.62 They further evaluated the molecular dynamics simulation with 
naloxone (Figure 2.2), the universal opioid antagonist, to MOR. At least three main 
binding domains of naloxone were observed: a polar and aromatic domain composed 
of Asp147, Phe289, Trp293, Cys321 and Tyr326, possibly involved in cation-π 
interactions with the protonated nitrogen of naloxone; a hydrophobic domain 
consisting of Tyr148 from TM3, Tyr210 and Phe221 from EL2 and another 
hydrophobic region involving Trp318, Leu219, Ile322, Ile296 and Ile144.62 Based on 
their mutational analysis and computational study, Li and coworkers reported that 
mutation of Asp164 in the highly conserved Asp-Arg-Tyr (DRY) motif in TM3 to 
either His, Gln, Tyr or Met resulted in constitutive activation of MOR.68             
Computational modeling based on the crystal structure of rhodopsin suggests the 
differences in conformation resulting from the mutation are probably due to changes 
in the interaction between the cytoplasmic ends of TM3 and TM6 involving the 
conserved Arg116 in TM3 and Arg280 in TM6.61 Very recently, conformational 
changes in the transmembrane domains of the constitutively active Asp164Tyr MOR 
were reported based on identification of accessible cysteine residues within the TM 
domains labeled by methanethiosulfonate ethylammonium (MTSEA).69  
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      As discussed earlier (Chapter 1, section 1.1), the low sequence homology between 
MOR and rhodopsin represents a potential for significant error in homology modeling 
experiments.70-72 One way to improve the accuracy of such theoretical model is by 
providing adequate receptor-specific (in this case opioid receptors) and ligand-
specific experimental constraints. Based on the above findings there is clearly a need 
to develop a more direct method to examine receptor-ligand interactions and the 














Figure 2.2. Morphine and morphine-derived alkaloids for MOR 

































































2.3 Ligands for MOR  
2.3.1 Small Molecule Ligands for MOR 
      Morphine, the prototypical MOR agonist, was first isolated from poppy seeds by 
Serturner in 1803. He named the compound after Morpheus, the Greek god of sleep 
and dreams.28 But it was more than a century later that the complex structure of 
morphine was confirmed through total synthesis by Gates and Tschudi.73, 74 Later, the 
relative stereochemistry of morphine was established by chemical synthesis and X-
ray crystallography.75 The absolute configuration (Figure 2.2) was later proved with 
application of various techniques.76 In addition to morphine, related alkaloids 
discovered in opium are codeine and thebaine77 (Figure 2.2). Although thebaine is not 
active as an analgesic, it serves as an important synthetic intermediate for the 
preparation of several other potent analgesics.78 The elucidation of the structure of 
morphine was followed by extensive structure-activity relationship (SAR) studies of 
analogs of morphine and related synthetic compounds including morphinans, 
benzomorphinans and phenylpiperidines. Some of the MOR selective agonists 
discovered from such studies include meperidine, fentenyl and methadone (Figure 
2.2) which are also routinely used for the treatment of pain, alone or in combination 
therapy, or opiate addiction (methadone, Table 2.1).  
      The antagonists naltrexone and naloxone (Table 2.1 and Figure 2.2) have been 
extensively used to study MOR pharmacology. These compounds also exhibit 
significant affinity towards DOR and KOR. Naloxone is primarily used to reverse  
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opiate overdose whereas naltrexone is employed for treatment of narcotic addiction 
and alcohol dependence. The antagonist cyprodime exhibits higher selectivity for  
MOR over DOR and KOR. 
Table 2.1 Opioid affinities and activity in guinea pig ileum (GPI) and mouse vas deference (MVD) of 
selected MOR agonists and antagonists79 
 
 
2.3.2 Opioid Peptides 
 
2.3.2.1 Endogenous Opioid Peptides Interacting with MOR 
      The first endogenous ligands for mammalian opioid receptors discovered back in 
1970s were the two pentapeptides: leucine and methionine enkephalin80 followed by 
dynorphin A81, 82 and β-endorphin.83 Since these peptides were structurally different 
from the alkaloid opiates, they were referred to as opioids to include all nonpeptides 
and peptides with opiate-like activity. All of these endogenous peptides share a 
common N-terminal tetrapeptide sequence (Tyr-Gly-Gly-Phe, Table 2.2), but they 
differ in their C-terminal sequences and also in their preferential interaction with 
different opioid receptor types. Based on this observation, Goldstein proposed the 
common N- terminal sequence as the ‘message’ sequence required for activation of 
opioid receptors and the unique C-terminal sequences as ‘address’ sequences which  
                      Ki  (nM)                       Ki ratio              IC50 (nM)  a. Agonists 
MOR DOR KOR MOR/DOR/KOR GPI MVD 
Morphine 1.8 90 317 1/50/175 28 478 
Meperidine 385 4,350 5,140 1/11/13 1,109 16,000 
Fentanyl 7.0 150 470 1/21/67 0.92 26 
Methadone 4.5 15 1,630 1/3.3/360 22 523 
                     Ki  (nM)                        Ki ratio                Ke (nM) b. Antagonists 
MOR DOR KOR MOR/DOR/KOR GPI MVD 
Cyprodine 9.4 356 176 1/38/19 31 6110 
Naloxone 1.8 23 4.8 1/13/2.7 1.9 12 
Naltrexone 1.1 6.6 8.5 1/6.0/7.7 0.36 3.6 
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Table 2.2 Mammalian opioid peptides with their precursor proteins 
 
 
provide the required affinity for a particular ligand for a particular opioid receptor 
type.84 Some synthetic enkephalin analogs and the amphibian peptide dermorphin 
(see below)85 interact with the MOR preferentially. Endomorphins which were 
relatively recently discovered by Zadina et al.86, 87 exhibit high affinity and highest 
selectivity for MOR among the endogenous mammalian peptides. Other enkephalin 
















Endomorphin-1 Tyr-Pro-Trp-PheNH2 Unknown 
Endomorphin-2 Tyr-Pro-Phe-PheNH2 
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analogs (e.g. DPDPE) as well as the deltorphin family of amphibian peptides88 
preferentially bind to DOR 89, 90 where as dynorphin A binds preferentially to KOR.91 
 2.3.2.2 MOR Selective Linear Enkephalin Analogs 
      The enkephalin class of opioid peptides has been extensively studied since their 
identification.89, 92-95 The endogenous enkephalins show some preference for binding 
to DOR but are labile to degradation by a variety of proteases. Therefore, extensive  
Table 2.3 Opioid receptor affinities and selectivity in the GPI and MVD of MOR selective enkephalin 
aIC50 values 
research has been carried out to develop modified analogs with increased metabolic 
stability and different selectivities. As a result both MOR and DOR selective 
enkephalin analogs have been identified.89, 92, 94, 95 For example, amidation, reduction, 
or complete elimination of the C- terminus results in analogs with retention of MOR 
affinity and an appreciable increase in MOR selectivity. DAMGO (Figure 2.3), the 
most commonly used MOR selective peptide ligand, is an example of a reduced C-
terminus with high affinity and selectivity for MOR (Table 2.3).99 Other related MOR 
 








MOR DOR MOR/DOR GPI MVD 
 
References 
DAMGO  1.9 345 180 4.5 33 79 
Syndyphalin-25  
(Tyr-D-Met-Gly-NMePheol) 
0.29a 1,250a 4300 0.0025 - 96 
LY 164929 (Figure 2.3) 0.6a 900a 1500 - - 97 
Tyr-cyclo[D-Dab-Gly-Phe-Leu]  13.8 1158 83 14.1 81.4 98 
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selective C-terminally modified tetrapeptide analogs include syndyphalin-25 (Table 
2.3),100 and LY164929 (Figure 2.3)97 that exhibit significantly higher MOR 
selectivity than DAMGO (Table 2.3). Also, the characteristic Tyr-Gly-Gly-Phe 
‘message’ sequence’ is not an absolute requirement for interaction with MOR, as 
replacement of the aromatic moiety of Phe4 with either a cyclohexane ring101 or a 
leucine side chain102, 103 were found to be well tolerated. 
 
2.3.2.3 MOR Selective Conformationally Constrained Enkephalin Analogs 
      Incorporation of conformationally constrained amino acids or a cyclic constraint 
has been a successful approach to obtain greater selectivity for one particular receptor 




































































constraint was (Tyr-cyclo[Nγ-D-Dab-Gly-Phe-Leu], Figure 2.3, Dab=α,γ-
diaminobutyric acid), which demonstrated both high affinity and improved selectivity 
towards MOR.104 In contrast, the acyclic linear analog [D-
Dab2,Leu5]enkephalinamide failed to show any MOR selectivity.105 Other cyclic 
analogs with either D-Orn or D-Lys in position 2 exhibited decreased selectivity for 
MOR, although these analogs show higher affinity for this receptor.98 The restriction 
of conformational flexibility in Tyr-cyclo[Nγ-D-Dab-Gly-Phe-Leu] was also 
demonstrated by NMR spectroscopy106, 107 and computational methods;106-110 
however, some degree of conformational flexibility remains  
especially for larger ring sizes. Receptor selectivity was also achieved by 
incorporating constrained amino acids. One such example is the modified 
[Leu5]enkephalin analog where replacement of Tyr1 by 2-amino-6-hydroxy-2-
tetralincarboxylic acid (Hat) results in increased selectivity for MOR.111 
2.3.2.4 MOR Selective Peptides from Amphibian Skin 
      Amphibian skin is a rich source of a varied range of peptides which often 
resemble the neurotransmitter or gastrointestinal hormones of mammalian systems.112 
In 1981, Montecuchhi et al. and Brocardo et al. first described dermorphin, a 
heptapeptide isolated from the skin of the South American frog Phyllomedusa 
sauvagei,113, 114 and another similar peptide containing hydroxyproline (Hyp) in place 
of Pro6 from the skin of  Phyllomedusa rohdei (Figure 2.4).115 Later in the 1990s, the 
sequences of three additional dermorphin peptides were predicted based on the cDNA 







Figure 2.4. Dermorphin peptides 
 
      The unique structural feature of the amphibian opioid peptides is the presence of 
D-Ala between the two aromatic residues Tyr1 and Phe3, in contrast to the message 
sequence Tyr-Gly-Gly-Phe for all of the enkephalins and most other mammalian 
opioid peptides. Considerable research was performed to identify the gene 
responsible for the D-amino acid in these peptides. It was found that the triplet codon 
for L-Ala was included in the dermorphin gene116, 117 leading to the hypothesis that 
the L-Ala residue must be converted to D-Ala through posttranslational 
modification.118 Kreil et al. rationalized that the mechanism of epimerization should 
be a quantitative inversion of the chiral center at the α-carbon of alanine, as opposed 
to racemization by a racemases which would result in an equal quantity of L-and D-
isomers.118, 119 However, a racemase mechanism should produce some level of 
detectable L-Ala dermorphin analogue, and no such isomer has been found in 






Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2       dermorphin 
Tyr-D-Ala-Phe-Gly-Tyr-Hyp-Ser-NH2      [Hyp6]dermorphin 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Lys-OH        [Lys7-OH]dermorphin  
Tyr-D-Ala-Phe-Trp-Tyr-Pro-Asn-OH        [Trp4,Asn7-OH]dermorphin 
Tyr-D-Ala-Phe-Trp-Asn-OH                      [Trp4, Asn7-OH]dermorphin 1-5 
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2.3.2.4.1 SAR Study of Dermorphins 
 
      Based on extensive in vitro studies binding assays on crude or synaptosomal 
preparations of brain membranes and bioassays on electrically stimulated GPI and 
MVD, dermorphins (Table 2.4) were found to be one of the most potent and selective  
Table 2.4. Affinities and MOR selectivity of natural dermorphins (amidated and acid forms) and 
biological activities on GPI and MVD. Taken from reference 119. 
 
    aDER= Dermorphin 
 
MOR agonists among the naturally occurring opioids.118 The primary peptide 
dermorphin shows 20 times higher affinity, and is 50 times more selective for MOR  
than morphine.118 [Lys7]dermorphin, obtained from skin of Phyllomedusa bicolor, 
exhibits 10 fold higher affinity and selectivity than DAMGO and dermorphin and is 
100 times more potent in the GPI and MVD functional assays than morphine (Table 
2.4). [Lys7]dermorphin has been further reported to differentiate between two MOR 
subtypes.120 
        Ki nM             Ki ratio             IC50 nM 
 
Peptide 
MOR DOR DOR/MOR GPI MVD 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 (Dermorphin) 0.54  929  1720 1.29  16.5  
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-OH - - - 4.5  28.1  
Tyr-D-Ala-Phe-Gly-Tyr-Hyp-Ser-NH2 0.65  1200  1846 1.6   18.1  
Tyr-D-Ala-Phe-Gly-Tyr-Hyp-Ser-OH - - - 4.9  33.0  
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Lys-NH2 0.09 1105 >10000 1.15 13.6 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Lys-OH 5.7  1150  201 3.82  56.3  
DER-Gly-Glu-Ala-Lys-Lys-Ile-NH2a 0.149 130 872 1.53   - 
DER-Gly-Glu-Ala-Lys-Lys-Ile-Lys-Arg-NH2a 0.002 7.2 3600 1.37   - 
Tyr-D-Ala-Phe-Phe-NH2  (TAPP) 1.5 625 417 255 780 
Tyr-D-Ala-Phe-Trp-Asn-NH2 0.9  480  533 5.00  73.7  
Tyr-D-Ala-Phe-Trp-Tyr-Pro-Asn-NH2 0.32  690  2156 0.58  6.6  
DAMGO 1.1  430  391 7.1  115  
Morphine 11.0  500 45 150  1215  
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     Comparisons of the MOR affinities of acid vs. amide versions of the naturally 
occurring dermorphins revealed that peptides with the C-terminal carboxylic acid 
derivatives had several-fold lower MOR affinities than that of the amidated 
peptides.121 The high potency of the C-terminally amidated dermorphin analogs 
occurs possibly as a result of suppression of the negative charge of the terminal 
carboxy group. Also, C-terminal amidation helps protect the analogs from possible 
cleavage by carboxypeptidases.118   Of the shorter dermorphin amide analogs, 
dermorphin (1-5) retains 50% and dermorphin (1-4) retains 5% of the potency in 
activating opioid receptors in GPI118 and dermorphin (1-3) was inactive.122 It was also 
found that 1-4 sequence of dermorphin is the primary end product of enzymatic 
degradation in rat brain.122 The affinities of C-terminally elongated dermorphin 
analogs which included residues from the precursor sequence were higher than 
dermorphin for MOR from rat brain, whereas in the GPI assay, the potencies were 
similar or slightly lower than that of dermorphin.121 Although a decrease in MOR 
affinity was observed with the introduction of additional residues through Glu9 or 
Ala10, probably due to the presence of acidic Glu9, further extension of the peptide 
with basic residues increases MOR affinity (Table 2.4).121 Affinity and selectivity of a 
dimeric derivative of dermorphin have also been investigated. Dimeric derivatives 
were prepared by bridging two monomers with hydrazine or diamines of various 
lengths.123 One of these ligands, di-dermorphin, where two dermorphin molecules are 
linked by hydrazine, displays 5-fold greater MOR affinity and similar selectivity as 
dermorphin. 
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       Extensive SAR studies with amino acid substitution in every position of 
dermorphin, have been reported in the literature including some of the shorter 
dermorphin sequences.85, 124-129 An alanine scan of dermorphin indicated that 
substitutions at positions 4, 6 and 7 were well tolerated. However, substitutions in 
position 1, 2, 3, or 5 resulted in large decreases in GPI potency.130 Modifications of 
Gly4 are well tolerated, particularly in the case of tetrapeptide analogs. When Gly4 
was replaced with sarcosine (NMeGly), in a tetrapeptide analog derived from 
dermorphin, an increase in opioid activity in antinociceptive assays was observed.131 
Another tetrapeptide amide analog of dermorphin obtained from substituting Gly4 
with Phe resulted in the dermorphin / enkephalin hybrid TAPP (Table 2.4) that is a 
potent and selective agonist at MOR.132 The substitutions of positions 3 and 4 of  
Table 2.5. Affinity and selectivity of dermorphin analogs including tetrapeptide analogs of dermorphin 






TAPP with bulky aromatic amino acids, e.g. tryptophan or naphthylalanine, are well 
tolerated and produce more lipophilic peptides.133 
       Numerous substitutions of the D-Ala2 residue between the two aromatic residues 
have been investigated. A substitution of D-Ala with the L-isomer results in a 100- 
             Ki nM         IC50 nM Peptide 
MOR DOR GPI MVD 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 0.54  929  1.29  16.5  
Tyr-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 2171 >40000 >4000 >15000 
Tyr-D-Met-Phe-Gly-Tyr-Pro-Ser-NH2 92.4 1340 47.0 249 
Tyr-D-Pro-Phe-Gly-Tyr-Pro-Ser-NH2 2400 1890 >50000 >50000 
Tyr-D-Arg-Phe-Gly-Tyr-Pro-Ser-NH2 3.9    - 92     - 
Tyr-D-Arg-Phe-Gly-NH2 1.7    - 10.8     - 
Tyr-D-Arg-Phe-Gly-OH 5.25    - 23     - 
Tyr-D-Arg-Phe-Lys-NH2 (DALDA) 1.69 >20000 254 781 
Tyr-D-Arg-Phe-Sar-OH (TAPS) 1.1   - 6.6     - 
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fold decrease in MOR affinity and abolishes activity in the GPI (<0.1% the potency 
of dermorphin, Table 2.5). Substitution of D-Ala2 in dermorphin with L-Tic (1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid), conformationally constrained analog of 
Phe L-Tic resulted in a DOR antagonist.134 Similarly, substitution with D-Pro2 
rendered the peptide nonselective and agonist activity was lost in the GPI assay 
(Table 2.5).118 Substitution of D-Ala2 with D-Met reduced binding to the MOR, 
whereas substitution with D-Arg resulted in analogs with either similar or in some 
cases increased MOR affinity and analgesic potency.118, 131, 135 The tetrapeptide 
analog TAPS (Table 2.5) was reported by Paakkari et al., to be a potent 
antinociceptive agent and caused respiratory stimulation rather than depression that 
was antagonized by naloxonazine- the putative MOR1 subtype antagonist.136 TAPS 
was also shown to antagonize the respiratory depression caused by dermorphin. These 
results have led to the proposal that TAPS is an agonist at the MOR1 subtype and an  
antagonist at the MOR2 subtype in vivo.136 Based on Schwyzer’s proposal that MOR 
are situated in an ionic membrane compartment,137 Schiller and coworkers 
hypothesized that positively charged ligands would display MOR selectivity.132 This 
hypothesis was supported by the results for  the tetrapeptide dermorphin derivative 
with a positively charged residue Lys in position 4 which exhibited increased MOR 
selectivity.132 The [D-Arg2,Lys4]dermorphin analog DALDA (Table 2.5), which 
contains a +3 net positive charge, also demonstrated superior MOR selectivity in 
binding assays. Quarternization of the side chain amine of Lys4 in DALDA was well 
tolerated and the resulting analogs retained potent in vivo antinociceptive activity in 
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the mouse writhing assay after s.c. administration.138 This antinociceptive effects 
were significantly reduced by the quarternized antagonist N-methyllevallorphan. This 
suggest that these analogs exhibit peripheral antinociceptive activity in this assay.138 
      Substitution of Tyr1 of DALDA by Dmt [(2,6-dimethyl) tyrosine] resulted in 
analog with 10-fold higher affinities for both MOR and DOR139 and 200 fold higher 
affinity for KOR.140 It was also found that in the rat tail flick test after i.t. 
administration, Dmt1[DALDA] was 220 and 3,000 times more potent than DALDA 
and morphine respectively. 141 
2.4 Affinity Labels 
      Although a considerable amount of information is available from the SAR of 
opioid ligands as well as from chimeric and site directed mutagenesis studies of 
opioid receptors, determination of the details of binding and ligand interaction with 
the receptor at the molecular level still remains a formidable challenge. To understand 
interaction of opioid receptors with their ligands at the molecular level, other 
approaches are needed. Affinity labels represent one such approach for probing the 
structure of membrane-bound proteins which cannot be readily solved by 
crystallography.142 Portoghese proposed that affinity labels bind to their receptors in a 






Figure 2.5. An illustration of the two steps involved in covalent binding of an affinity label to its 
target. Taken from reference 143 
 
affinity of the ligand for the target site, and the second step (Figure 2.5, receptor type 
A) involves proper alignment of an electrophilic group on the affinity label with a 
compatible, receptor-based nucleophile that is in close proximity. Because of the 
second irreversible step, high receptor selectivity is theoretically possible, and affinity  
labels can detect subtle differences in receptor-ligand interactions. As indicated in 
Figure 2.5, in receptor type B the affinity label fails to undergo the second recognition 
process since it does not have sufficient reactivity to bind to the nearby nucleophile. 
Alternatively, if a reactive electrophile is too far away from the nucleophile on the 
receptor (Figure 2.5, receptor type C), then the second irreversible binding will not 
occur. Therefore, affinity labels undergoing irreversible binding to the receptor can be 
highly useful in differentiating different opioid receptor types. Site specific 
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interactions can be obtained by determining the attachment point of an affinity label 
to its receptor providing important information about the location and orientation of 
opioid ligands.143  
      Depending upon the nature and chemical reactivity of the functionality, affinity 
labels can be classified as electrophilic affinity labels, which are inherently reactive, 
or photoaffinity labels which require photoactivation to achieve the reactive state. It 
should be pointed out that a ligand with extremely high affinity but without the 
capability of binding covalently can also be considered an affinity label; but a Kd 
value of not greater than 1 X 10-12 M is required. 142 
2.4.1 Photoaffinity Labels 
      Photoaffinity labels are functionalities that can be activated by a brief exposure to 
light to generate a highly reactive intermediate species. Because of the high reactivity 
of these photolyzed intermediates, they often bind indiscriminately to nearby 
functionalities in the receptor binding site.142 Therefore, whether or not a 
photoaffinity label will bind to a particular opioid receptor type is determined 
primarily by its selectivity as a reversible ligand in the first recognition step. Some 
examples of photoreactive intermediates are the nitrene from the azido functionality 
and the carbene from diazo or diazirine functionalities (Figure 2.6).144  
 
Figure 2.6. Precursors of reactive species in photoaffinity labels144  
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      The first photoaffinity label for an opioid receptor was the [3H]norlevorphanol 
derivative APL (Figure 2.7), prepared by Winter and Goldstein 145 APL exhibited 
irreversible binding when it was photolyzed in the presence of the GPI or opioid 
receptors in the mouse brain particulate fraction, but the binding was not effectively 
blocked by levorphanol suggesting extensive non-specific binding. Later, when the 
N-methyl quaternary derivative of APL, MAPL (Figure 2.7) was synthesized and 
subsequently tested on mouse brain and GPI, MAPL showed some degree of 
irreversible binding.146 Some other examples of photoaffinity labels for opioid  
 
Figure 2.7. A: Photoaffinity labels for opioid receptors, B: Amino acid or acid derivative of 
photoaffinity labels used to characterize opioid receptors. 
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receptors are diazoketone and arylazide derivatives of fentanyl designed by 
Maryanoff and coworkers147 (Figure 2.7). Later, Peers and coworkers reported the 
synthesis of the nitro-azido derivative of 14β-aminomorphinone (NAM, Figure 2.7) 
which is a full antagonist in both the GPI and MVD preparation. Although NAM 
appears to bind selectively to MOR in binding studies, it is not suitable for labeling 
opioid receptors because of its slow irreversible binding.148  
     There have been reports of several enkephalin-based photoaffinity label analogs 
with an azido group as the photoaffinity functionality (Table 2.6). Amongst these, 
only a few are selective for MOR. Some of the azido-containing photoaffinity labels 
for MOR reported are a DAMGO-based peptide (Tyr-D-Ala-Gly-Me-Phe(pN3)-
Glyol, ~ 0.3 µM to irreversibly label 50% of MOR sites) prepared by Garbay-
Jaureguiberry and coworkers,149 and a photoaffinity label derivative of  the 
somatostatin based MOR selective antagonist CTAP (D-Phe-cyclo[Cys-(p-N3Phe)-D-
Trp-Lys-Thr-Pen]-Thr-NH2, IC50 = 48.6 nM) reported by Landis et al150 however, it 
was not reported whether this analog bound irreversibly to MOR. 












       The main disadvantage of using the azido group as a photoaffinity label for 
opioid receptors is that the short wavelength (~250 nm) of UV irradiation generally 
used to generate the reactive species can inactivate opioid receptors.151 In order to 
overcome this problem 4-azido-2-nitrobenzoic acid (ANB) or Bpa (p-benzoyl-
phenylalanine), Figure 2.7) can be used as the photoaffinity label group. These 
functionalities shift the wavelength required for photolysis to longer wavelengths, 
which may prevent opioid receptor inactivation; this was shown by Herblin and 
coworkers when they reported synthesis and selective binding of a tetrapeptide 
morpheceptin analog containing Bpa (Tyr-Pro-Phe-Bpa-NH2) to MOR.152 However 
this analog showed only modest affinity for MOR (IC50 = 0.27 µM), and only 25% of 
the receptor was inactivated upon photolysis in the presence of 2.8 µM of this 
compound at a wavelength of 300-350 nm.152 The bulk of this amino acid (Bpa) may 
interfere with receptor-ligand interactions which could limit its incorporation to 
positions in the C-terminal sequence.  
2.4.2 Electrophilic Affinity Labels 
      When the affinity label contains an electrophilic functionality, several factors may 
affect the selectivity of such a label: 1) receptor affinity for the ligand, 2) selectivity 
of ligand for the receptor 3) selectivity and chemical reactivity of the electrophile, and 
4) proximity of the electrophile to a nearby nucleophile on the receptor. Since two 
recognition steps are involved in irreversible binding, in some cases increased 
receptor selectivity can be achieved, depending upon the reactivity and proximity of 
an appropriate nucleophile in the receptor (see Figure 2.5). Therefore, an electrophilic 
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affinity label can be a useful tool to selectively label one opioid receptor type among 
multiple types. 
2.4.2.1 Small Molecule-Based Electrophilic Affinity Labels: β-Funaltrexamine 
and Other Analogs 
      The first successful electrophilic affinity label for opioid receptors was prepared 
by Portoghese and coworkers by incorporating a nitrogen mustard at the 6β position 
of naltrexamine, resulting in β-chlornaltrexamine (β-CNA, Figure 2.8).153, 154 A 
nitrogen mustard is a highly reactive electrophile, and as such this affinity label 
bound irreversibly to all opioid receptor types. It should be noted that only one of the 
chloroethyl groups is needed for the irreversible binding.155 Another example of 
nitrogen mustard-containing opiate analogs in the literature, such as the oxymophone 
analog β-chloroxymorphamine (β-COA).156, 157  
      In order to improve the receptor selectivity of opiate-derived affinity labels, 
Portoghese and co-workers prepared the β-fumaramide derivative β-funaltrexamine 
(β-FNA, Figure 2.8), which contains a less reactive electrophile, in place of the 
nitrogen mustard at the 6β position of naltrexamine.158 The resulting compound 
bound irreversibly to MOR where it acts an antagonist, whereas it is a reversible 
agonist at KOR. Whether or not β-FNA binds irreversibly to DOR remains 
unclear.159, 160 It was also shown that the configuration and orientation of the 
fumaramide are important for irreversible binding to MOR. Neither the 6α analogue 
of β-FNA nor the 6β-maleimide derivative with a cis double bond were capable of 




Figure 2.8. Small molecule electrophilic and reporter affinity labels for MOR 
 
      β-FNA was the first affinity label whose point of attachment to an opioid receptor 
was successfully determined.52 Liu-Chen and coworkers used molecular biology and 
protein isolation techniques to identify the attachment point. Initially, based on the 
binding of [3H]β-FNA to MOR / KOR receptor chimeras, a region of MOR spanning 
from the third intracellular loop to the C-terminus was determined to be essential for 
irreversible binding.51 However, upon isolation and partial purification of the labeled 
receptor, the point of attachment was found to be in the EL2-TM5 region (Figure 
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2.9). Subsequently, site directed mutagenesis of amino acid residues in this region 
identified Lys233 as the attachment point (Figure 2.9).52 This finding of the 
attachment point is significant since Lys233 is conserved in all three opioid receptor 
types. It appears that the selectivity of β-FNA for MOR is due to the differences in  
 
Figure 2.9. Location of the attachment point (Lys233) of β-FNA to  MOR. Taken from reference 52 
 
the tertiary structures of the receptors. This observation further reinforces the utility 
of affinity labels as a direct approach to studying receptor-ligand interactions. 
      A number of 14β-amino substituted derivatives of naloxone and morphine were 
prepared by Archer and coworkers.161-163 Reactive functionalities that were attached 
to the 14β-amino group include bromoacetamide, thioglycolamide and cinnamoyl 
groups. Among these, the p-nitro-substituted derivative with a 5β-methyl group 
MET-CAMO (Figure 2.8) appeared to bind irreversibly to MOR.162, 163 This was also 
the first N-methyl derivative reported with long-lasting MOR selective antagonist 
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activity with no agonist activity. Similarly, the p-chloro substituted derivative MET-
Cl-CAMO (Figure 2.8) also bound irreversibly to MOR and was a long-lasting MOR 
selective antagonist.164 
      Other examples of MOR selective affinity labels are hydrazone derivatives of the 
6-ketone of naloxone, naltrexone and oxymophone described by Pasternak and 
coworkers,165-167 and the etonitazene derivative BIT designed by Rice and co-workers 
(Figure 2.8). 168, 169 
      Portoghese and coworkers reported the design of ‘reporter affinity labels’ by 
attaching an o-phthaladehyde group to the opioid antagonists naltreaxamine and 6’- 
and 7’- aminonaltrindole.170-173 This unique approach was based on the reaction of a 
o-phthaladehyde with an amine and thiol (from Lys and Cys side chains in the 
receptor), resulting in a fluorescent isoindole; detection of a fluorescence indicates 
that a covalent reaction has occurred. Recently, the attachment points of the reporter 
affinity label naltrexamine naphthalene dialdehyde derivative NNA (Figure 2.8) to 
MOR was determined using site-directed mutagenesis.174 Lys233 and the adjacent 
Cys235 of TM5 were determined to be the residues involved in isoindole formation, 
as mutation of either of these residues prevented the generation of the fluorescent 
product. Although this method allows the determination of attachment points without 
isolating the labeled receptor, this approach is limited by the requirement of two 
specific nucleophilic receptor residues in close proximity to one another and the 
reactive functionality on the ligand. 
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2.4.2.2 Peptide-Based Electrophilic Affinity Labels 
      Although a number of nonpeptide affinity labels for opioid receptors have been 
reported in the literature, peptide-based affinity labels have been limited to mainly 
photoaffinity labels (section 2.4.1). Since endogenous ligands for opioid receptors are 
peptides, it is important to understand the interactions between peptides and opioid 
receptors at the molecular level. Peptide-based electrophilic affinity labels present a 
useful class of pharmacological tools which can provide valuable information 
regarding the binding of opioid peptides to their receptors.  
      The first peptide-based electrophilic affinity labels were reported by Pelton and 
workers in 1980.175 The C-terminal chloromethyl ketone derivatives of leucine-
enkephalin (Tyr-Ala-Gly-Phe-Leu-CH2Cl) (DLECK) and its D-Ala2 analog [D-
Ala2,Leu5]enkephalin (DALECK) were prepared as potential affinity labels. Although 
the compounds exhibited high potency at the opioid receptors in the GPI, the analogs 
failed to show any irreversible activity in this tissue.175 Szucs et al. later 
reinvestigated the biological effects of these compounds and reported 50% 
irreversible blockade of [3H]naloxone binding to opioid receptor sites in rat brain 
membranes by both peptides.176 The triated derivative of DALECK was later 
prepared by Newman and Barnard and the preferential binding of this peptide to 
MOR was demonstrated. Moreover, they were able to determine the molecular weight 
of MOR (58 KDa) based on detection of the labeled receptor on a gel. However, the 
attachment point on MOR could not be determined.177 There have been a few other 
examples of electrophilic affinity labels reported for MOR. Benyhe and coworkers 
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reported the chloromethyl ketone analog) of DAMGO (Tyr-D-Ala-Gly-(Me)Phe-
CH2Cl) which resulted in concentration-dependent irreversible inhibition of 
[3H]naloxone binding with an IC50 of 1-5 µM. Shimohigashi and coworkers in 1992 
reported the use of the 3-nitro-2-pyridinesulphenyl (Npys) group in a enkephalin and 
morphiceptin analogs. Among these, the enkephalin analog (Tyr-D-Ala-Gly-Phe-
Leu(CH2SNpys) produced irreversible inhibition of [3H]DAMGO binding in a 
concentration-dependent manner. The concentration required to label half of the 
receptors was 19 nM.178 
      Research in our group has focused on designing and synthesizing peptidic affinity 
labels for MOR based on endomorphins, dermorphin or DAMGO as the parent 
ligand. These ligands were modified by incorporating either a bromoacetamide or an 
isothiocyanate functionality as the electrophile (Table 2.7). The affinities and 
selectivity of these peptides were evaluated in radioligand binding assays using 
Chinese hamster ovary (CHO) cells expressing MOR and DOR. 
       In the endomorphin series of analogs, the para positions of either Phe3 or Phe4 
was modified by incorporation of an amino functionality, which was then further 
derivatized to yield the bromoacetamide and isothiocyanate analogs.179 Although the 
analogs retained selectivity for MOR, they all exhibited lower affinities than 
endomorphin (IC50 = 4.2 nM) in binding experiments. The highest affinity analog in 








Table 2.7 Progress towards developing peptide-based affinity labels for MOR: analogs of 
endomorphin, DAMGO and  dermorphin. 
  
 
Parent peptide Affinity Label 
Modifications 
Effect on  MOR Affinity 





IC50 = 4.20 ± 0.07 nM for X = H 
X = -NCS,  
       -NHCOCH2Br 
Affinity decreased >1000 fold179 
Tyr-Pro-Phe-Phe(p-X)NH2 
 
IC50 = 4.20 ± 0.07 nM for X = H  
X = -NCS,  
       -NHCOCH2Br 





IC50 = 0.51 ± 0.1 nM for X = H  
X = -NCS,  
       -NHCOCH2Br 





IC50 = 0.72 ± 0.07 nM for X = H 
X = -NCS,  
       -NHCOCH2Br 





IC50 = 1.89 ± 0.2 nM for X = H 
X = -NCS,  
       -NHCOCH2Br 
X= -NCS, affinity decreased >200 fold 
 
 X = -NHCOCH2Br, 
      IC50= 27.7 ± 3.5 nM 
 
Did not exhibit wash-resistant 





IC50 = 1.04 ± 0.05 nM for X = H 
X = -NCS,  
       -NHCOCH2Br 
  X= -NCS,  IC50= 92.8 ± 17.0 
  X= -NHCOCH2Br,  
      IC50 = 15.1 ± 2.4 nM 
 
Did not exhibit resistant inhibition of 
binding to MOR181 
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      Following the same design strategy, analogs of DAMGO were also prepared by 
modifying the para position of NMePhe4. However, in every instance MOR affinity 
decreased over 1000 fold.180 
      Analogs of dermorphin and [Lys7]dermorphin were designed by modifying both 
the ‘message’ and ‘address’ regions of the peptides.181 Introduction of an electrophile 
in the ‘message’ region (the para position of Phe3) decreased MOR affinity by >1000 
fold, whereas changes in ‘address’ region in both dermorphin and [Lys7]dermorphin 
were well tolerated. [Phe(p-NHCOCH2Br)5]- and [Phe(p-
NHCOCH2Br)5,Lys7]dermorphin showed high affinity for MOR (IC50 = 27.7 and 
15.1 nM, respectively). However, none of the analogs in either the dermorphin or 
[Lys7]dermorphin series showed wash-resistant inhibition of  binding, and hence they 
were not affinity labels for MOR.181 
2.5 Significance: Peptide vs Small Molecule-Based Affinity Labels 
      Since pain relief is mediated mainly through MOR, it is important to understand 
the interactions between MOR ligands and the receptor. The endogenous ligands of 
the opioid receptors are peptides, and studies of chimeric opioid receptors and site-
directed mutagenesis suggest that peptide ligands may interact differently with opioid 
receptors than non-peptide ligands.22 Therefore, information about interactions of 
peptide ligands with opioid receptors is complimentary to that obtained for non-
peptide ligands. Moreover, information obtained from chimeric and site-directed 
mutagenesis studies is complicated by the potential alteration of the secondary and / 
or tertiary structure of receptor protein. Electrophilic affinity labels, which interact in 
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a two-step non-equilibrium manner, can provide direct information about ligand 
binding to the receptor at the molecular level. Hence, peptide-based affinity labels can 
be utilized as valuable pharmacological tools to provide information about the 
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       Narcotic analgesics produce pain relief generally through activation of µ opioid 
receptors (MOR), but the use of these analgesics is limited by their side effects, 
namely respiratory depression, tolerance, constipation and physical dependence.1 
Therefore, there is an ongoing need to develop novel analgesics with fewer side 
effects. Understanding receptor-ligand interactions at the molecular level can 
facilitate the design of novel opioid ligands. Since the cloning of the three major 
opioid receptors, MOR, δ opioid receptors (DOR) and κ opioid receptors (KOR), in 
the 1990s and determination of their sequences,2, 3 there have been considerable 
advancements in understanding opioid receptor-ligand interactions. These studies 
have utilized chimeric receptors (such as MOR/KOR chimeras, etc.) and site-directed 
mutagenesis.4 Although these approaches have provided considerable information 
regarding receptor-ligand interactions, interpreting the results can be complicated by 
changes in the secondary and / or tertiary structures of the protein.4 Also while these 
approaches provide information about which residues in the receptor may interact 
with the ligand, they often do not provide information about what portions of the 
ligand are involved in these interactions. 
      Currently, there is no high-resolution crystal structure available for any of the 
opioid receptors. The only transmembrane receptor proteins in the GPCR family 
whose crystal structures have been solved are the human β2 adrenergic receptor,5, 6 
bovine rhodopsin in its dark state bound to 11-cis retinal,7, 8 and very recently a 
crystal structure of rhodopsin in its G-protein interacting conformation.9 To date, all 
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of the computational models of opioid receptors were based on homology modeling 
using crystal structures of rhodopsin bound to retinal. Very recently Xu and 
coworkers have proposed several key features of monomer and homodimers forms of 
MOR based on the crystal structure of ligand-free opsin.10 However, the main 
disadvantage of these methods is the lack of amino acid sequence identity between 
opioid receptors and rhodopsin. In order for this method of comparative modeling to 
be reasonably accurate, 50% or higher identity between target and template protein is 
desired,4 but comparison of opioid receptor sequences and rhodopsin indicate only 
~20% identity of all residues and ~29% identity in the TM regions.4 Therefore, 
automated homology modeling of rhodopsin and opioid receptors may generate many 
errors, mostly from misalignment of sequences.11-13 One way to improve the accuracy 
of such theoretical models is by utilizing adequate receptor specific (in this case 
opioid receptor) experimental constraints. This can only be achieved through 
understanding the interactions of opioid ligands with the receptors at the molecular 
level. 
      Since pain relief is mediated mainly through MOR, it is important to understand 
the interactions between MOR ligands and their receptor. The endogenous ligands of 
the opioid receptors are peptides, and studies of chimeric opioid receptors and site-
directed mutagenesis suggest that peptide ligands may interact differently with opioid 
receptors than non-peptide ligands.4 Therefore, structural information obtained from 
interactions of peptide ligands with opioid receptors can be complimentary to that 
obtained for nonpeptide ligands.  
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3.2 Background  
      Affinity labels, which are ligands that interact with their target in a non-
equilibrium manner,14 can provide detailed information about specific receptor-ligand 
interactions,15, 16 and the information obtained from affinity labels can compliment 
results obtained from molecular biology and computational methods. Affinity labels 
can be either photoaffinity or electrophilic affinity labels. Among the electrophilic 
affinity labels, the naltrexamine derivative β-funaltrexamine (β-FNA), a well studied 
affinity label for MOR, was the first electrophilic affinity label (and one of only two 
affinity labels17) for opioid receptors whose covalent attachment point (Lys233 in 
MOR) has been successfully determined.16  
      Although a number of nonpeptide affinity labels for opioid receptors have been 
reported in the literature,14 until recently peptide-based affinity labels have been 
limited mostly to photoaffinity labels.14 An azido-containing photoaffinity label 
derivative of DAMGO (Tyr-D-Ala-Gly-MePhe(pN3)-Gly-ol)18 and a Bpa (p-benzoyl-
L-phenylalanine)-containing tetrapeptide analog of morpheceptin19 are early examples 
of peptide-based photoaffinity labels for MOR. A disadvantage of using azido- 
containing photoaffinity labels is that short wavelength UV irradiation generally used 
to generate the reactive species can inactivate opioid receptors.20 Alkylation of the 
receptor by electrophilic affinity labels, on the other hand, depends on the selectivity 
and chemical reactivity of the electrophile, and thus is not subject to the receptor 
inactivation that can occur with photoaffinity labels. Examples of peptide-based 
electrophilic affinity labels, selective for DOR, that have been reported include [D-
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Ala2,Cys6]enkephalin (DALCE),21 the chloromethyl ketone of [D-
Ala2,Leu5]enkephalin (DALECK),22  and isothiocyanate and bromoacetamide-
containing TIPP (Tyr-Tic-Phe-Phe) derivatives discovered in our laboratory.23, 24, 25 
There have been very few reports of electrophilic peptide-based affinity labels 
selective for MOR. The chloromethyl ketone of [Tyr-D-Ala-Gly-
(NMe)Phe]enkephalin-1-4 (DAMK, IC50 = 1-5 µM for concentration dependent 
irreversible inhibition of [3H]naloxone binding)26 and Tyr-D-Ala-Gly-Phe-
Leu(CH2S)Npys (Npys = 3-nitro-2-pyridinesulphenyl, IC50 = 19 nM for concentration 
dependent irreversible inhibition of [3H]DAMGO binding)27  are the only examples of 
peptide-based electrophilic affinity labels for MOR reported in the literature. Previous 
attempts in our group to prepare affinity labels for MOR by incorporating an 
electrophilic functionality such as a bromoacetamide or isothiocyanate at the para 
position of either Phe3 or Phe4 in endomorphin-2 (Tyr-Pro-Phe-PheNH2) were 
unsuccessful because the modified analogs exhibited large (40- to 80-fold) decreases 
in MOR binding affinity compared to the parent peptide endomorphin-2.28 
3.3 Dermorphin and Previous Dermorphin-Based Analogs  
      Dermorphin (Figure 3.1), an endogenous peptide from South American frog 
skin,29 was selected as the parent ligand for further modification in the present study. 
Dermorphin is a highly selective ligand with 100-fold higher affinity than morphine 
for MOR.29 In 1981, Montecuchhi et al. and Brocardo et al. first identified 








Figure 3.1. Structure of dermorphin 
 
dermorphin analog with hydroxyproline (Hyp) in place of Pro6 from the skin of 
Phyllomedusa rohdei.32 The characteristic feature of the frog skin peptides are their 
N-terminal tripeptide Tyr-D-aa-Phe sequence, which constitutes the ‘message’ 
domain33 of these peptides (see Chapter 2.3.2.4.1 for details). This sequence is 
distinct from the well established tetrapeptide message sequence Tyr-Gly-Gly-Phe for 
the enkephalins and most of the mammalian opioid peptides. 
       The D-configuration at position 2 of dermorphin is critical for MOR binding and 
opioid activity.29 Substitution of D-Ala with L-Ala results in a 100-fold decrease in 
MOR affinity and GPI activity.29 There have been a number of reports of structure 
activity relationship (SAR) studies on position 2 of dermorphin. It was found that 
substituting D-Ala with a conformational constrained residue like D-Pro reduces the 
peptide’s affinity for MOR by 5000 fold.29 However, replacement of D-Ala with a 
larger amino acid (e.g. D-Arg) is well tolerated, and D-Arg-substituted dermorphin 
analogs either retain, or in some cases exhibit increased, MOR affinity and analgesic 























(Tyr-D-Arg-Phe-Lys-NH2)34 and TAPS (Tyr-D-Arg-Phe-Ser-OH)35 which exhibit 
high affinity for MOR in rat brain and potent antinociception. 
      C-Terminal amidation among the naturally occurring dermorphins has been 
found to have some beneficial effect on MOR affinity, when compared to C-terminal 
acid peptides.29 This is thought to be due to the absence of repulsive interactions with 
the negative charge on the C-terminal acid derivative and also to increased resistance 
against carboxypeptidase-mediated cleavage.29 
3.3.1 Dermorphin-Based Affinity Labels 
      In a previous effort by our group to design potent affinity labels selective for 
MOR, the para position of either Phe3 in the ‘message’ sequence or a Phe in position 
5 in the ‘address’ sequence of dermorphin were modified with either an 
isothiocyanate or a bromoacetamide functionality as a reactive electrophile.36 These 
substitutions, however, resulted in large decreases in MOR affinity. In fact, p-
isothiocyanate substitution on Phe3 was better tolerated by DOR, and the resulting 
analog exhibited higher affinity for DOR than MOR (Table 3.1). Compared to Phe3 
substitution, Phe5-substituted analogs were generally better tolerated by both MOR 
and DOR (Table 3.1). Among the analogs [Phe(p-NHCOCH2Br)5]dermorphin 
showed reasonable binding affinity (IC50 = 27.7 nM), and hence was examined for 
wash-resistant inhibition of binding  to MOR using [3H]DAMGO as the radioligand. 
Unfortunately, this ligand failed to show any evidence of irreversible binding.36 In a 
related series of analogs, Ser7 of dermorphin was replaced with Lys and the  
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Peptide IC50 (nM) 
   MOR 
IC50 (nM) 
   DOR 
Dermorphin   
 
0.72 ± 0.08 197 ± 28 
Phe3 modifications       
 
X1 = NH2,  41.5 ± 7.2 >10000 
X1 = NCS,  650 ± 720 238 ± 42 
X1 = NHCOCH2Br,   1140 ± 190 8040 ± 1050 
Phe5 modifications  
 
[Phe5]dermorphin  
X1 = H,  
1.89 ± 0.18 218 ± 14 
X1 = NH2 2.79 ± 0.74 212 ± 34 
X1 = NCS 159 ± 21.8 1430 ± 280 
X1 = NHCOCH2Br 27.7 ± 3.5 373 ± 126 
[Phe5,Lys7]dermorphin  
 
X1 = NH2 1.04 ± 0.05 476 ± 73 
X1 = NCS 92.8 ± 17.0 5760 ± 1390 
X1 = NHCOCH2Br 15.1 ± 2.4 707 ± 142 
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corresponding Phe5-substituted analogs of [Phe5,Lys7]dermorphin showed 
approximately 2-fold higher MOR affinity compared to the corresponding Ser7 
analogs, like the Ser7 analogs [Phe(p-NHCOCH2Br)5,Lys7]dermorphin (IC50 = 15.1 
nM, Table 3.1) did not appear to bind irreversibly to the receptor.36 
3.4 Rationale for the Design of New Affinity Labels 
      In the present study, we chose an alternative location in the ‘message’ sequence, 
position 2, to incorporate a reactive functionality. Larger D-amino acids are tolerated 
at this position in peptides by MOR29 (see section 3.3 above), suggesting that 
introduction of a functionality such as an affinity label into the side chain of this 
residue would be tolerated by the receptor. In the present study, D-Ala at position 2 
was replaced by either D-Orn or D-Lys. The free amine on the side chain of these 
amino acids was used as a suitable handle to incorporate the electrophilic 
bromoacetamide or isothiocyanate functionalities (Figure 3.2). This strategy also 
permits varying the length of the amino acid side chain to optimize binding of the 
affinity label to its receptor. For this series of analogs, [D-Orn(COCH3)2]- and [D-
Lys(COCH3)2]dermorphin served as reversible control peptides for the respective 




Figure 3.2. Potential affinity label derivatives for MOR and the corresponding reversible control 
peptides based on the parent peptide dermorphin 
 
3.5 Results and Discussion 
      The potential affinity labels (1, 2, 4 and 5) and the reversible controls (3 and 6) 
were successfully prepared following a solid phase synthetic protocol developed 
previously in our group (Scheme 3.1).25, 37 Purification of the analogs was carried out 
by reversed phase preparative HPLC. All of the analogs (1-6) were obtained >97% 
purity as determined by analytical HPLC (Table 3.2). 
      Each of the peptides 1-6 displayed subnanomolar to low nanomolar affinity for 
MOR in  in standard radioligand binding assays.38 Of the analogs prepared, 1, 2 and 4 
exhibited the highest affinities for MOR (subnanomolar IC50 values); their affinities 
were substantially higher than the corresponding Phe3-substituted analogs (IC50 = 40-
6050 nM).36 In addition, these three potential affinity labels exhibit equal (peptide 1) 
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or higher affinity (7 and 2 times higher for analogs 2 and 4, respectively) than the  
 
 
Scheme 3.1: Fmoc-based solid phase synthesis of the peptide affinity labels based on the parent 
peptide dermorphin 
 
Table 3.2: Analytical data for dermorphin analogs 1-6 
 
A 5-50% gradient of MeCN over 45 min at a flowrate of 1 mL / min was used.  
aSystem 1 = 0.1% trifluoroacetic acid (TFA) in aq. MeCN 







tR /Purity (%) 
 
System 2b
tR (min) / Purity (%) 
Calculated M+H+ Observed 
M+H+ 
1 [D-Orn(=C=S)2] 22.7/ 100 20.86/97.6 888.3 888.3 
2 [D-Orn(COCH2Br)2] 15.77/ 99.5 14.2/97.9 966.3, 968.3 966.3, 968.3 
3 [D-Orn(COCH3)2] 12.37/ 100.0 10.99/100 888.4 888.4 
4 [D-Lys(=C=S)2] 23.51/ 99.5 22.18/98.6 902.0 902.0 
5 [D-Lys(COCH2Br)2] 16.88/ 100.0 23.69 /97.5 980.3, 982.3 980.3, 982.3 
6 [D-Lys(COCH3)2] 13.67/ 100.0 12.27/100 902.4 902.4 
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aRelative to dermorphin (IC50 MOR-dermorphin / IC50 MOR-compound. [3H]DAMGO ([D-
Ala2,MeNPhe4,glyol]enkephalin) and [3H]DPDPE (cyclo[D-Pen2,D-Pen5]enkephalin) were used as 
radioligands for MOR and DOR respectively. 
b IC50 (DOR)/IC50 (MOR). 
c From ref. 37 
 
parent peptide dermorphin.       
      The two isothiocyanate-containing potential affinity labels in the two series (D-
Orn and D-Lys) exhibit similar binding affinities for MOR, while the affinity of the 
bromoacetamide derivative 2 in the D-Orn series is 60-times higher than the 
corresponding D-Lys derivative 5. Similarly, the acetylated control compound in the 
D-Orn series, 3, exhibits significantly higher affinity than the corresponding control 
compound 6 in the D-Lys series (Table 3.3). Clearly, the lengths of the side chain in 
the D-Orn and D-Lys analogs as well as the identity of the attached functionality can 
influence binding of the dermorphin analogs to MOR. The differences in the affinities 
could be due to several factors, including steric and / or electronic properties that 
affect the interactions of the side chain with the receptor binding site. 
      Comparing the affinities of these peptides for DOR, the isothiocyanate derivative 
in the D-Orn series, 1, exhibits unexpected high affinity for DOR, 4 times higher than 
the affinity of the corresponding analog 3 in the D-Lys series. The acetylated control 
 






MOR DOR   
1 [D-Orn(=C=S)2] 0.81 ± 0.29 23.8 ±2.1 0.89 29 
2 [D-Orn(COCH2Br)2] 0.11 ± 0.02 342 ± 20 6.54 3110 
3 [D-Orn(COCH3)2] 4.25 ± 0.35 272 ± 23 0.17 64 
4 [D-Lys(=C=S)2] 0.38 ± 0.08 97.1 ±4.9 1.89 255 
5 [D-Lys(COCH2Br)2] 5.23 ± 2.31 382 ± 22 0.14 73 
6 [D-Lys(COCH3)2] 29.8 ± 7.6 436 ±  34 0.02 15 
Dermorphinc 0.72 ± 0.07 197 ± 28 1.0 274 
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compounds and bromoacetamide analogs in both series (compounds 2, 3, 5 and 6) 
show much lower affinity for DOR compared to 1 and 4, and lower DOR affinity than 
the parent peptide dermorphin; no other major differences in DOR affinities was 
observed between the two series (Table 3.3). 
          Except for the isothiocyanate derivative 1, the D-Orn series of compounds are 
more selective for MOR over DOR than the corresponding D-Lys compounds. The 
potential affinity label derivative with the highest apparent selectivity is [D-
Orn(COCH2Br)2]dermorphin, 2, which exhibits >3000-fold difference in the IC50 
values for MOR over DOR, 50-fold more selective than the reversible control 
compound 3 and 11-fold more selective for MOR than the parent peptide dermorphin 
(Table 3.3). In contrast, [D-Lys(COCH2Br)2]dermorphin, 5, exhibits 4-fold lower 
selectivity for MOR compared to dermorphin due to the large decrease in MOR 
affinity. For the isothiocyanate derivatives, however, the trend for selectivity is 
reversed. The D-Orn(=C=S)2 derivative 1 is 9-fold less selective for MOR than 
dermorphin and also 2-fold less selective than [D-Lys(=C=S)2]dermorphin, 4 (Table 
3.3). The selectivities were calculated using IC50 values which are a function of 
radioligand concentrations used; therefore comparisons of the selectivities for these 
peptides to those reported in other studies should be made with caution. 
      Since all four potential affinity labels showed subnanomolar to nanomolar affinity 
for MOR, they were examined to determine whether they may bind covalently to 
MOR. Wash resistant inhibition of [3H]DAMGO binding by these four analogs, 1, 2, 
4 and 5, at their IC50 values was determined according to the procedure described 
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previously.39 The acetylated derivatives 3 and 6 were included as reversible controls 
to verify that the washing procedure completely removed noncovalently bound 
compound. The washing procedure removed >80% of both reversible control 
peptides. In the D-Orn series, [D-Orn(=C=S)2]dermorphin (1) at its IC50 value (0.43 
nM) caused 40 ± 8% loss of [3H]DAMGO binding compared to control membranes 
(P<0.001) even after extensive washing (Figure 3.3), suggesting that this peptide  
bound covalently to a nearby nucleophile in the binding site of MOR.40  
       
Figure 3.3.: (A) Wash-resistant inhibition of binding of [D-Orn2]dermorphin (1-3)  and (B) [D-
Lys2]dermorphin (4-6) derivatives. The concentration of the peptide in the incubations are  indicated in 
parenthesis. *= p<0.05, ***=p<0.01 compared to control membranes 
 
      In contrast, although [D-Orn(COCH2Br)2]dermorphin (2) shows the highest MOR 
affinity (IC50 = 0.11 nM) of all the compounds tested, this peptide did not exhibit 
wash-resistant inhibition of binding to MOR at a concentration equal to its IC50 of 
0.11 nM (Figure 3.3), but was effectively removed by the washing procedure. 
However, when the wash-resistant inhibition of binding experiments were repeated at 
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higher concentrations (1 and 10 nM) this analog did show statistically significant 
concentration-dependent wash-resistant inhibition of binding (P<0.001) compared to 
control membranes (Figure 3.4). In the D-Lys series, both the bromoacetamide and 
isothiocyanate derivatives exhibit statistically significant (P<0.001) inhibition of  
[3H]DAMGO binding after extensive washing; the inhibition of [3H]DAMGO  
 







Figure 3.4: Concentration-dependent wash-resistant inhibition of binding of dermorphin analogs: A: 
[D-Orn(-COCH2Br)2]dermorphin (2), B: [D-Lys(=C=S)2]dermorphin (4). ***=p<0.001 compared to 
control 
 
binding by compounds 4 and 5 was 31 ± 2%  for both compounds (Figure 3.3). 
Moreover, compound 4 produced concentration-dependent wash-resistant inhibition 
of [3H]DAMGO binding at higher concentrations of 4 and 40 nM (P<0.001, Figure 
3.4). 
      Time dependent wash-resistant inhibition of binding of the affinity labels 1-4 will 
be carried out in the near future. Since 1 exhibited considerable affinity for DOR 





      In conclusion, we have successfully identified a series of dermorphin-based 
affinity label analogs that show exceptionally high affinity (IC50 = 0.1-5 nM) for 
MOR in standard binding assays. These analogs were designed by modifying position 
2 of dermorphin, which is a new strategy for designing peptide-based affinity label 
derivatives of opioid peptides that has not been previously reported. This resulted in a 
substantial improvement in MOR binding affinity (between 10- to 100-fold) 
compared to the previous dermorphin-based analogs synthesized in our laboratory in 
which the para position of Phe3 or a Phe in position 5 of dermorphin or 
[Lys7]dermorphin were modified.36 Three of the four potential affinity labels in the 
present study show subnanomolar affinity for MOR, indicating the side chains in [D-
Orn(X)2]dermorphin (X= -COCH2Br or =C=S) and [D-Lys(=C=S)2]dermorphin are 
well tolerated in the binding pocket of MOR. All four potential affinity labels (1, 2, 4 
and 5) exhibit wash-resistant inhibition of binding to MOR. This suggests that these 
compounds likely bind covalently to MOR. 
      Comparison of the binding affinities reported for previous MOR selective affinity 
labels and the analogs prepared in the present study indicate that the dermorphin-
based affinity labels have substantially higher MOR affinity. Previously Tyr-D-Ala-
Gly-Phe-Leu(CH2S)Npys was reported to be the highest affinity (IC50 = 19 nM in 
radioligand binding assays) peptide-based electrophilic affinity label for MOR, 
although it lacked selectivity and also showed similar affinity for DOR (IC50 = 12 nM 
in radioligand binding assays).27 Importantly, three of these four affinity labels, [D-
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Orn(=C=S)2]- (1), [D-Orn(-COCH2Br)2]- (2)  and [D-Lys(=C=S)2]dermophin (4) 
appear to have higher affinity (approximately 3- to 20-fold) than the well-studied 
nonpeptide MOR affinity label β-FNA (IC50 = 2.2 nM in radioligand binding 
assays).15, 41 With the successful identification of the peptide-based electrophilic 









      The PAL-PEG-PS (peptide amide linker-polyethylene glyol-polystyrene) resin 
and DIEA (N,N-diisopropylethylamine) were purchased from Applied Biosystems 
(Foster City, CA). 1-Hydroxybenzotriazole (HOBt) and benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBOP) were purchased from 
Novabiochem (San Diego, CA). Piperidine was purchased from Aldrich Chemical 
Company (Milwaukee, WI), and the standard Fmoc (9-fluorenylmethoxycarbony) -
protected L-amino acids were purchased from Novabiochem. Fmoc-D-Lys(Aloc)-OH 
and Fmoc-D-Orn(Aloc)-OH were purchased from Bachem (San Carlos, CA). 
Bromoacetic acid and 1,1’-thiocarbonyldiimidazole (TCD) were purchased from 
Acros Organic (New Jersey). Phosphoric acid was purchased from ICN Biomedicals 
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Inc. (Aurora, OH). All HPLC-grade solvents (acetonitrile, N,N-dimethylformamide 
(DMF), dichloromethane (DCM), and methanol), acetic acid, diethyl ether and 
triethylamine used for peptide synthesis or HPLC were purchased from Fisher 
Scientific Co. (St. Louis, MO).  TFA was purchased from Pierce (Rockville, IL). 
 
Synthesis of dermorphin analogs 
 
The peptide analogs were synthesized by solid phase peptide synthesis according to 
methods previously developed in our laboratory.37 Amino acids used for synthesis 
were Fmoc protected except for the N-terminal Tyr which was Boc (tert-
butyloxycarbonyl) protected. The side chain protecting groups were tBu for Ser and 
Tyr, and Aloc (allyloxycarbonyl) for D-Orn or D-Lys. Peptide synthesis was carried 
out on a high load PAL-PEG-PS resin (0.38 to 0.40 mmol/g, Scheme 3.1).37 The 
coupling reactions for the five C-terminal residues (Phe-Gly-Tyr-Pro-Ser) were 
performed on a CS Bio (model CS336) automated peptide synthesizer generally for 
2.5 h; the couplings generally used a 4-fold excess of amino acid with PyBOP and 
HOBt (4 equiv each) as the activating reagents and DIEA (8 equiv) as the base in 
DMF except where noted. Coupling of Fmoc-D-Lys(Aloc) and Fmoc-D-Orn(Aloc) 
were performed manually for 2 h using a 2-fold excess of the amino acid with PyBOP 
and HOBt (2 equiv each) and DIEA (4 equiv) in DMF. Completion of the reactions 
was confirmed by either a negative ninhydrin test for coupling to a primary amine or 
a negative chloranil test for coupling to a secondary amine. Fmoc deprotection was 
achieved using 20% piperidine in DMF (2 x 20 min); the resin was then washed with 
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DCM:DMF (1:1, 10 min). The N-terminal amino acid Boc-Tyr(tBu)-OH was then 
coupled manually (4-fold excess) using PyBop, HOBt (4-fold excess each) and DIEA 
(8-fold excess) in DMF. After peptide chain assembly, the Aloc group was 
deprotected using a catalytic amount of tetrakis triphenylphosphine palladium(0) (0.1 
equiv) in DCM twice for 30 min, in the presence of phenyl silane (24 equiv) as a 
scavenger for the allyl group.37, 42 After the deprotection, the resin was washed 
extensively following a published procedure.37, 43 The resin (300 mg) was then 
divided into three parts. One part (100 mg) was treated with a large excess (~20 
equiv) of acetic anhydride in DMF (3-4 mL) for 40 min to obtain the reversible 
control compound. To obtain the isothiocyanate derivative, the second part of the 
resin (100 mg) was treated with thiocarbonyldiimidazole (TCD, 4 equiv) in a 
minimum amount of DMF (3 mL) for 4 h. To obtain the bromoacetamide derivative 
the remaining part of the resin (100 mg) was reacted with bromoacetic acid (10 equiv) 
and N,N-diisopropylcarbodiimide (DIC, 8 equiv) overnight. The bromoacetic acid 
was preactivated with DIC in a minimal amount of DMF (3 mL) and then this 
mixture was added to the resin. The completion of these reactions was confirmed by a 
negative ninhydrin test.  
3.7.2 Cleavage from Resin 
      Each part of the resin was then cleaved by treating with 95% TFA and 5% water 
(total volume 1.5 mL) for 2 h, followed by filtration. For the acetylated reversible 
controls, the peptide cleaved from the resin was diluted with 3-4 mL of 10% aqueous 
acetic acid and then back extracted with ether (2 x 2 mL). The aqueous layer was 
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collected and lyophilized to give the crude peptide. For the affinity label peptides, 
extraction with ether was not carried out. Instead, the TFA solution was concentrated 
under nitrogen, diluted with 10% acetic acid (3-4 mL) and lyophilized to give the 
crude products. 
3.7.3 Purification and Analysis 
      The crude peptides were purified by preparative reversed-phase HPLC (Shimadzu 
LC-6AD system equipped with a Shimadzu SPD-10AVP detector) on a Vydac C18 
column (10µ, 300 Å, 22 x 250 mm). For the affinity label analogs (1, 2, 4 and 5) the 
purified fractions were immediately lyophilized to avoid potential degradation of the 
affinity labels by water acting as a nucleophile.  For purification, a linear gradient of 
5-50% aqueous MeCN containing 0.1% TFA over 45 min at a flow rate of 20 mL/min 
was used. The purification was monitored at 214 nm and 280 nm.  
      The purity of the final peptides was verified by analytical HPLC (Shimadzu LC-
10ATVP system equipped with a Shimadzu SPD-10AVP detector) with a Vydac C18 
column (5µ, 300Å, 4.6 x 50 mm). The purity was evaluated in two solvent systems. A 
linear gradient of 5-50% solvent B at a flow rate of 1 mL/min was used; the eluents 
were monitored at 214 and 280 nm. For system 1, solvent A was 0.1% TFA in water 
and solvent B was 0.1% TFA in MeCN. For system 2, solvent A was 0.09 M TEAP at 
pH 2.5 and solvent B was MeCN.44 Molecular weights of the pure peptides were 
verified by ESI-MS mass spectroscopy (Table 3.2) using a Waters LCT Premier time 
of flight mass spectrometer. 
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3.7.4 Pharmacological Assays 
      The purified peptides were examined for affinity for MOR and DOR following 
standard radioligand binding assays using [3H]DAMGO and [3H]DPDPE, 
respectively, as the radioligands. Based on the binding affinities and selectivity 
obtained from initial radioligand binding experiments, compounds 1-6 were then 
further evaluated for wash-resistant inhibition of binding of [3H]DAMGO to MOR. 
3.7.4.1 Radioligand Binding Assays 
      Radioligand binding assays for compounds 1-6 were performed using membranes 
derived from Chinese hamster ovary (CHO) cells stably expressing MOR and DOR. 
CHO cells were harvested at confluency in 25 mM Tris buffer (pH 7.4) and 
centrifuged at 40,000g for 25 min. The pellets were resuspended using 25 mM Tris 
buffer, pH 7.4. This procedure was repeated 3 times. Incubations were carried out in 
triplicate with varying concentrations of peptides (0.1 nM to 10 µM) for 90 min at 
room temperature using 1 nM [3H]DAMGO and 0.15 nM [3H]DPDPE as radioligands 
for MOR and DOR, respectively. Binding assays were performed in the presence of 
protease inhibitor cocktail (10 µM bestatin, 3 µM captopril and 50 µM L-leucyl-L-
leucine) and 3 mM Mg2+. To determine the nonspecific binding, 10 µM of unlabeled 
DAMGO and DPDPE was used for MOR and DOR, respectively. The reactions were 
stopped by filtration using a 48 or 96-well Brandel cell harvester. The filters were 
incubated with scintillation cocktail (9.5 mL) with shaking for at least 6 h. The 
radioactivity was then measured by scintillation counting for 5 min. 
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3.7.4.2 Wash-Resistant Inhibition of Binding Assays23 
 
      CHO cells stably expressing MOR were homogenized in 25 mM Tris buffer (30 
mL), pH 7.4, using a Dounce glass tissue homogenizer (Pestle A, 10-12 times) and 
centrifuged at 40,000 g for 25 min. The pellets were resuspended using 25 mM Tris 
buffer, pH 7.4, and this procedure of centrifugation-resuspension was repeated  for a 
total of 3 times. The CHO membrane homogenates (9.9 mL at 200 µg/mL protein) 
were preincubated in borosilicate glass tubes in the presence or absence of 100 µL of 
experimental peptides (1-6) at the final concentrations indicated in Figures 3.3 and 
3.4. Each tube was gently inverted 3 times every 15 min. After 90 min incubation, the 
homogenates were centrifuged at 40,000 g for 15 min. The pellets were resuspended 
in 25 mM Tris (8 mL) using a teflon / glass homogenizer. For each sample a separate 
homogenizer was used to avoid cross-contamination. The centrifugation and 
resuspension steps were repeated for a total of 5 washes. After the fifth 
centrifugation, the pellets were homogenized in 25 mM Tris buffer, pH 7.4 (12 mL). 
The radioligand binding assay was then performed as described above. The results are 
expressed as percentage of control membranes that were preincubated in the absence 
of compounds (Figures 3.3 and 3.4).  
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      There are three main classes of opioid receptors: µ, δ and κ, which belong to the 
superfamily of G-protein coupled receptors (GPCR).1 Among these, µ opioid 
receptors (MOR) have been the main target of opioid analgesics.2 Although the 
clinically important opioid analgesic agents, e.g. morphine, methadone, fentanyl and 
related drugs, produce pain relief through activation of MOR, these agents are also 
associated with severe side effects, namely respiratory depression, constipation, 
tolerance and physical dependence.1  
      In order to develop potent analgesics with less severe side effects it is imperative 
to understand the interaction of opioid ligands with their receptors at the molecular 
level. Morphine, the prototypical MOR agonist, and the related analogs are non 
peptide in nature, but the endogenous ligands for MOR, which were identified after 
successful characterization of multiple opioid receptors in the 1970s, were found to 
be peptides.3, 4 The endogenous mammalian opioid peptides for MOR are the 
enkephalins, β-endorphin,5 Met-enkephalin-Arg-Phe,6 endomorphin-I and 
endomorphin-II.7, 8 Since different ligands (peptide vs nonpeptide) may interact 
differently with receptors,9 information obtained from the interactions of peptides 
with receptors can be complimentary to that obtained about the interactions of non-
peptidic ligands.  
     Currently, there is no high-resolution crystal structure available for any of the 
opioid receptors. The only transmembrane receptor proteins in the GPCR family 
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whose crystal structures have been solved are the human β2 adrenergic receptor,10, 11 
rhodopsin in its dark state bound to 11-cis retinal,12 and very recently the crystal 
structure of rhodopsin in its G-protein interacting conformation.13 To date, all of the 
computational models of opioid receptors were based on homology modeling starting 
from crystal structure of rhodopsin bound to retinal. However, the main disadvantage 
of this method is the lack of sequence homology between amino acid sequences in 
opioid receptors and rhodopsin. Therefore, homology modeling of opioid receptors 
based on rhodopsin may generate a number of errors, mostly from misalignment of 
sequences.14-16 One way to improve the accuracy of such theoretical models is by 
utilizing receptor specific (in this case opioid receptor) experimental constraints. 
      Since the cloning of the three major opioid receptors in the 1990s and 
determination of their sequences,17, 18 there have been considerable advancements in 
understanding opioid receptor-ligand interactions. The study of chimeric receptors 
and receptors containing point mutations has revealed the complexity of receptor-
ligand interactions, including differences between the interactions of the same ligand 
with different receptors as well as differences in interactions of different ligands with 
the same receptors.9 These data should be interpreted with caution, as changes in the 
primary sequence of a receptor could have significant effects on the secondary and / 
or tertiary structure of the receptor protein which in turn can affect the affinities of 
various ligands.9 Use of a more direct pharmacological approach could avoid this 
potential problem. 
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      Affinity labels, compounds that bind to their receptors in a non-equilibrium 
manner, can provide specific information based on the attachment point of the ligands 
to their receptors19 which can then be used as ‘anchor points’ to evaluate and improve 
current computational models for receptor-ligand interactions. Therefore, affinity 
labels can be utilized as complimentary pharmacological tools to existing molecular 
biology techniques and computational models. An affinity label, as described in 
chapter 2, consists of two different structural elements: an affinity core that binds to 
the binding site in the receptor, and a reactive group (i.e. an electrophillic group or 
photoaffinity label) to bind covalently to the receptor. In the first step, the affinity 
label binds to the receptor in a reversible manner. In the second step, depending upon 
the reactivity of the affinity label and its proximity to a nearby functionality on to the 
receptor, the affinity label may undergo irreversible binding to the receptor. This 
second step can provide additional selectivity to the ligand for a given receptor.19 
Among electrophiles, Michael acceptors, halomethylketones and isothiocyanate have 
been commonly used.19 A number of non-peptide based affinity labels for opioid 
receptors have been reported in the literature. Among these β-FNA (β-
funaltrexamine), a fumarate methyl ester derivative of naltrexone, has been one of the 
most extensively used affinity label derivative for opioid receptors.20 This is the first 
of only two affinity labels whose point of attachment to any opioid receptor (Lys233 
in TM 5) has been identified.21, 22 Portoghese and co-workers recently identified the 
attachment points of a reporter affinity label, an analog of naltrexamine containing a 
fluorogenic naphthalene dialdehyde moiety, to Lys233 and Cys235 of MOR.23   
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      As mentioned earlier, because of potential differences in the interactions of 
peptide and non-peptides with opioid receptors,9 complimentary information can be 
obtained from peptide-based affinity labels. However, peptide-based affinity labels 
have mostly been limited to photoaffinity labels.19 Early examples of peptide-based 
photoaffinity labels for MOR are an azido containing analog of DAMGO (Tyr-D-
Ala-Gly-MePhe(pN3)-Gly-ol)24 and a tetrapeptide analog of morpheceptin containing 
Bpa (p-benzoyl-L-phenylalanine).25 However, a disadvantage of using azido 
containing photoaffinity labels is that the short wavelength UV irradiation generally 
used to generate the reactive species can inactivate opioid receptors.26 Alkylation of 
the receptor by electrophilic affinity labels, on the other hand, depends on the 
selectivity and chemical reactivity of the electrophile, and the receptors are not 
subjected to the photoinactivation that can occur with photoaffinity labels. Examples 
of peptide-based electrophilic affinity labels, selective for δ opioid receptor (DOR), 
that have been reported include [D-Ala2,Cys6]enkephalin (DALCE),27 the 
chloromethyl ketone of [D-Ala2,Leu5]enkephalin (DALECK),28 and isothiocyanate 
and bromoacetamide-containing TIPP (Tyr-Tic-Phe-Phe) derivatives discovered in 
our laboratory.29-31 There have been very few reports of electrophilic peptide-based 
affinity labels selective for MOR. The chloromethyl ketone of Tyr-D-Ala-Gly-
(NMe)Phe (DAMK, IC50 = 1-5 µM for dose-dependent irreversible inhibition of 
[3H]naloxone binding)32 and Tyr-D-Ala-Gly-Phe-Leu(CH2SNpys) (Npys = 3-nitro-2-
pyridinesulphenyl, IC50 = 19 nM for irreversible inhibition of [3H]DAMGO 
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binding)33  are the only examples of peptide-based electrophilic affinity labels for 
MOR reported in the literature. 
 
4.2 DAMGO-Based Affinity Labels: Design Strategy 
     Continuing our effort to design new, selective and potent peptide-based affinity 
labels for MOR, we chose DAMGO, a highly potent and selective agonist for MOR,34 
as a parent ligand for further modification (Figure 4.1). DAMGO is 200-fold selective 
for MOR over DOR and shows negligible affinity for kappa opioid receptors 
(KOR).34 DAMGO was identified from a series of analogs based on the  
 
Figure 4.1. DAMGO (Tyr-D-Ala-Gly-NMePhe glyol) 
 
 
tetrapeptide Tyr-D-Ala-Gly-MePhe-OH34 which was identified earlier by 
modification of enkephalin (Tyr-Gly-Gly-Phe-Leu(Met)-OH).34 The substitution of a 
D-amino acid in position 2 of the enkephalin resulted in enzymatically stable 
analogs.35 Because of its high affinity and selectivity for MOR, DAMGO is routinely 
used to characterize MOR and thus represents an attractive lead ligand to design 
affinity labels. There has been only one report of a photoaffinity label derivative of 
DAMGO in the literature. Tyr-D-Ala-Gly-NMePhe(p-N3)glyol is a DAMGO-based 
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photoaffinity label with similar selectivity as DAMGO for MOR but with lower 
affinity than the parent compound (Ki = 25 nM).24 A higher concentration of the 
photoaffinity probe (0.3 µM) was required to label 50% of the MOR population, 
making the labeling experiments very challenging.24 Moreover, the UV wavelength 
(254 nm) used for photoactivation of the receptor bound ligand could potentially 
inactivate the opioid receptor.26  
      As an alternative strategy, electrophillic affinity labels were designed by 
incorporating either a bromoacetamide or an isothiocyanate functionality at the para 
position of NMePhe4 by another member in our research group (Figure 4.2). However 
  
Figure 4.2. Previously designed DAMGO-based affinity labels 
 
the modified analogs exhibited >1000-fold decrease in MOR affinity, and thus this 
modification was not tolerated by MOR at all (Table 4.1).36 
Table 4.1 Binding affinity of previously prepared DAMGO affinity labels. 
 
 
       
             DAMGO  Analogs             MOR IC50 ± SEM (nM) 
DAMGO                 0.51 ± 0.1 
[N-MePhe(p-NH2)4]DAMGO                 160 ± 35 
[N-MePhe(p-NCS)4]DAMGO              2490 ± 1070 
[N-MePhe(p-NHCOCH2Br)4]DAMGO              1210 ± 52 
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        With the success of the highly selective and high-affinity dermorphin-based 
electrophillic affinity labels (Chapter 3), we utilized the same design strategy to 
develop DAMGO-based affinity labels for MOR. Therefore, we substituted D-Orn or 
D-Lys in position 2 of DAMGO (D-Ala2) and attached a bromoacetamide or an 
isothiocyanate as the electrophilic functionality to the side chain amine of the D-




Figure 4.3. Potential affinity labels for MOR and the corresponding reversible control peptides based 
on the parent peptide DAMGO 
  
4.3 Results and Discussion 
      The synthesis of the DAMGO-based potential affinity labels was carried out on 
3,4-dihydro-2H-pyran-2-ylmethoxymethyl polystyrene (DHP-HM) resin following 





4.3.1 Loading of Fmoc-Gly-ol onto the DHP-HM Resin and Synthesis of 
DAMGO Analogs 
      To introduce the glyol functionality into the proposed DAMGO derivatives, the 
first step of the synthesis (Figure 4.4) involved loading of Fmoc-Glyol onto the DHP-
HM resin in the presence of pyridinium p-toluene sulfonate (PPTS) in dichloroethane 
 
Figure 4.4. Loading of Fmoc-Glyol onto the DHP-HM resin. 
 
(DCE).38 The percentage loading was determined by Fmoc quantitation which is 
based on measuring the absorbance of the dibenzofulvene adduct formed by 
deprotection of the Fmoc group from the resin following treatment with piperidine. 
The loading was 91%, which is within acceptable limits. 
      With the Fmoc-Glyol loaded DHP-HM resin in hand, the syntheses of the 
proposed DAMGO derivatives (Scheme 4.1) were then carried out according to the 
solid phase peptide synthesis protocol described in Chapter 3 (section 3.7.1). 





















Scheme 4.1 Synthetic scheme for DAMGO analogs. 
       
4.3.2 Side Reaction: Formation of Cyclic O-Alkyl Thiocarbamates 
      Although the synthesis and purification of the acetamide and bromoacetamide 
derivatives 2, 3, 5 and 6 proceeded smoothly (Table 4.2), analyses of the 
isothiocyanate containing DAMGO analogs revealed a side reaction. The analysis of 
purified fractions from the attempted synthesis of 4, [D-Lys(=C=S)2]DAMGO, by 






tBu Pd(PPh3)4 (0.1 equiv)

















aD-AA: D-Orn or D-Lys





1. D-AA = D-Orn
4. D-AA = D-Lys
2. D-AA = D-Orn
5. D-AA = D-Lys3. D-AA = D-Orn
6. D-AA = D-Lys
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had the same molecular weight ([D-Lys(=C=S)2]DAMGO, 613.2), but the fractions 
differed in their HPLC retention times by ~8 min  (Table 4.3 and Figure 4.5). A 
similar patterns in HPLC and mass spectra were seen in the case of the attempted 
synthesis of [D-Orn(=C=S)2]DAMGO, 1. Therefore, we investigated the side reaction 
by characterizing fractions A and B of  4. 
Table 4.2 Analytical data for DAMGO analogs 2, 3, 5 and 6 
5-50% gradient of MeCN over 45 min at a flowrate of 1 mL/min were used.  
aSystem 1 = 0.1% TFA in aq. MeCN 
bSystem 2 = 0.09 M TEAP and MeCN 




Table 4.3 HPLC retention times and molecular weights of two pure fractions (A and B) obtained from 
















tR (min) / Purity (%) 
Calculated M+H+ Observed 
M+H+ 
2 [D-Orn(COCH2Br)2]- 14.05/ 98.4 10.03/ 98.0 677.2 677.2, 679.2c 
3 [D-Orn(COCH3)2]- 8.85/ 100.0 6.88/ 98.0 599.3 599.3 
5 [D-Lys(COCH2Br)2]- 13.14/ 97.4 11.15/ 97.0 691.2 691.2,693.2c 
6 [D-Lys(COCH3)2]- 10.04/ 97.8 8.35/ 85.3 613.7 613.3 
Fraction  System 1a (tR) 
 
Observed M+H+
A 8.72 613.2 
B 15.35 613.2 
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Minutes







































Figure 4.5. HPLC spectra of fractions A (top) and B (bottom) obtained during purification of the 
products obtained from the attempted synthesis of [D-Lys(=C=S)2]DAMGO, 4, in a 15-50% gradient 
of MeCN containing 0.1% TFA over 45 min at a flowrate of 1 mL/min. 
 
      When the fractions were investigated the following day, the MS/MS of both 
fractions were identical, suggesting that one of the samples could have degraded to 
yield the second product. Subsequent analytical HPLC using the same gradient as 
above showed a major peak at 8.72 min for both fractions, indicating that fraction B 
had converted to A. Based on these results, it was proposed that the linear [D-








4.3.2.1 Proposed Side Reaction:  
      Based on the hypothesis mentioned above, the following possible side products 
were proposed (Figure 4.6):39 
Figure 4.6. Reactions for the formation of two possible cyclic O-alkyl thiocarbamates. Here [D-
Lys(=C=S)2]DAMGO is shown as the example. 
 
      In reaction (a) (Figure 4.6), the C-terminal glyol functionality acting as a 
nucleophile attacks the electrophilic carbon of the isothiocyanate functionality, 
resulting in the cyclic O-alkyl thiocarbamate I. Alternately, in reaction (b), the phenol 
of the N-terminal Tyr could attack the carbon in the isothiocyanate to form cyclic 
thiocarbamate II. Both I and II and the linear analog have the same molecular weight 
(613.2). Dermorphin analogs containing an isothiocyanate functionality ([D-
Orn(=C=S)2]dermorphin and [D-Lys(=C=S)2]dermorphin Chapter 3) which have a 
similar N-terminal sequence did not show any side reactions involving formation of a 
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cyclic thiocarbamate. Based on this reaction (a) seems to be the one which is more 
likely to have occurred. To identify the compounds, the peptides were characterized 
by Fourier transform infrared (FTIR) and nuclear magnetic resonance (NMR) 
spectroscopy.39 
 
4.3.2.2 Characterization of the Side Products: FTIR of Fr A and Fr B 
       If either of the proposed reactions (Figure 4.6) occurs, then one of the fractions A 
or B would show IR stretching for the isothiocyanate functionality and the other 
would not because of the formation of the cyclic product (either I or II, Figure 4.6). 
Figure 4.7 shows the IR spectra of fractions A and B, analyzed as KBr pellets. The IR 
spectra of  fraction A did not show any bands characteristic of an isothiocyanate 
functionality (around 2100-2200 cm-1), whereas fraction B has a distinct band around 
2189 cm-1 (Figure 4.7) which is characteristic of the isothiocyanate functionality. 
These results are consistent with our hypothesis that a thiocarbamate cyclic product  





























Figure 4.7. IR spectra of fractions A (top) and B (bottom) obtained from the attempted synthesis of 
[D-Lys(=C=S)2]DAMGO, 4. Fraction B shows isothiocyanate stretching at around 2100-2190 cm-1 
(indicated by arrow), whereas fraction A does not. 
 
4.3.2.3 Characterization of the Products by Proton NMR  
      Next, we used NMR to determine which of the two proposed products (Figure 
4.6.) were formed from the cyclization reaction. Table 4.4 shows the chemical shifts 
of relevant functional groups. As can be seen from the table, both fractions showed a 
singlet at 9.35 ppm corresponding to the phenol functionality of the N-terminal Tyr. 
5 0 01 0 0 01 5 0 02 0 0 02 5 0 03 0 0 03 5 0 04 0 0 0




1 2 . 5
1 5
1 7 . 5
2 0











































F T IR M e a s u re m e n t
5 0 01 0 0 01 5 0 02 0 0 02 5 0 03 0 0 03 5 0 04 0 0 0
1 / c m
7 . 5
1 5
2 2 . 5
3 0








































This result rules out the possibility of reaction (b) (Figure 4.6) since there would be 
no Tyr phenol proton in this potential side product. Fraction A did not show any peak  
 
Table 4.4 1H NMR data of fractions A and B obtained from the attempted synthesis of [D-
Lys(=C=S)2]DAMGO, 4 
 
Fraction δ (ppm) Corresponding Functional Groupa 
No broad peak around 3.4 No glyol (OH) A 
9.35 (singlet) Tyr phenol 
3.4 (broad) Glyol B 
9.35 (singlet) Tyr phenol 
aexchanged upon treatment with D2O 
for the glyol hydroxyl group (around 3.4 ppm), suggesting that this functionality was 
not involved in the side reaction; and hence the identity of the cyclic O-alkyl 
thiocarbamate in fraction A is structure I (Figure 4.7). Fraction B showed a broad 
band around 3.4 ppm (Table 4.4), characteristic of an aliphatic hydroxyl group, i.e 
from the glyol functionality, indicating that fraction B is the desired linear 
isothiocyanate containing peptide. As expected for hydroxyl groups, the peaks at 3.4 
and 9.35 were exchangeable with D2O. 
4.3.3 Radioligand Binding and Wash-Resistant Inhibition of Binding Assays  
      Since compounds 1 and 4 resulted in unstable side products, these two 
compounds were not subjected to radioligand binding assays. The other four 
DAMGO analogs 2, 3, 5 and 6 were tested for their binding affinity to both MOR and 
DOR, stably expressed on CHO cells, following the standard procedure. These results 
are shown in Table 4.5  
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      Compounds 2, 3, 5 and 6 exhibited very high affinity towards MOR in the range 
of 0.4 - 1 nM (Table 4.5). The binding affinities of all of the analogs for MOR were 
comparable to that of DAMGO (Table 4.5). Therefore, modification by incorporating 
derivatives of either D-Orn or D-Lys to DAMGO derivatives were well tolerated by 
MOR. As far as selectivity is concerned, compounds 3, 5, and 6 showed an IC50 ratio 
of >100-fold, whereas the bromoacetamide analog 2, [D-Orn(COCH2Br)2]DAMGO, 
showed somewhat higher affinity for DOR and therefore lower selectivity for MOR. 
However, the bromoacetamide analog in the D-Lys series, compound 5, exhibited 
high selectivity for MOR over DOR (237 fold, Table 4.5). Thus, the difference in side 
chain length in D-Lys vs. D-Orn (one less methylene group in D-Orn) influenced the 
binding affinity for DOR.       
      Compounds 2, 3, 5 and the 6 were also examined for wash-resistant inhibition of 
[3H]DAMGO binding to MOR according to the established procedure (see Chapter 
3). The washing procedure effectively removed control compound 3 in the D-Orn2 
series, (Figure 4.8). As seen in Figure 4.8, compound 2 exhibited >40% inhibition of 
IC50 





DAMGO  Analogs MOR DOR (DOR/MOR) 
2 [D-Orn(COCH2Br)2] 0.45 ± 0.06   33.1 ± 0.9 73 
3 [D-Orn(COCH3)2] 0.58 ± 0.11 102 ± 6 176 
5 [D-Lys(COCH2Br)2] 0.45 ± 0.25   103 ±  1 229 
6 [D-Lys(COCH3)2] 1.13 ± 0.22   268 ± 28 237 
DAMGO 0.51 ± 0.01 281 ± 20 550 
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[3H]DAMGO binding to MOR compared to untreated control membranes. This 


























Figure 4.8. Wash-resistant inhibition of  binding of [D-Orn2]DAMGO analogs 2 and 3. The 
membranes were incubated with the peptides at the concentrations indicated in parentheses.   
 
thus be an affinity label for MOR. However, the corresponding analog 5 in the D-Lys 
series [D-Lys(COCH2Br)2]DAMGO, 5, was removed by washing (Figure 4.9). 
Therefore, 5 may not appear to be affinity label for MOR. It is important to note that 
the small difference in the side chain of the amino acid at the 2nd position (D-Orn in 
the case of 2 and D-Lys in the case of 5) could have a significant effect on covalent 
binding to opioid receptors. The discovery of this new DAMGO-based electrophilic 
affinity label 2 demonstrated a successful strategy for developing peptide-based 
affinity labels through fine tuning the position of the affinity label to facilitate 



























Figure 4.9. Wash-resistant inhibition of binding by [D-Lys2]DAMGO analogs: 5 and 6 
 
4.3.4: Overcoming the Side Reaction: Design and Synthesis of DAMGA ([D-
Ala2,N-MePhe4,Gly5]enkephalinamide) Analogs. 
      Since the DAMGO-based isothiocyanate analogs  [D-Orn(=C=S)2]DAMGO, 2, 
and [D-Lys(=C=S)2]DAMGO, 4, resulted in the formation of cyclic O-alkyl 
thiocarbamate derivatives, these isothiocyanate analogs was not tested for binding to 
MOR. As discussed earlier, characterization of the linear peptide and cyclic side 
product revealed that the C-terminal glyol functionality participated in the formation 
of the cyclic product. Therefore, in order to overcome the side reaction, we modified 
the C-terminal glyol functionality. 
     The C-terminal glyol functionality was replaced by the glycyl amide functionality 
which can not participate in the cyclization. The bromoacetamide and the reversible 
acetylated control compounds for both [D-Orn2]- and[ D-Lys2]DAMGA were also 
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prepared, as indicated in Figure 4.10, to compare their affinities for MOR with the 










































Figure 4.10.  Modifications incorporated in the DAMGA analogs 
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derivatives of DAMGO was successfully overcome by replacing the glyol with a 
glycylamide. The isothiocyanate analogs 7 and 10 (Table 4.6) were successfully 



























tBu Pd(PPh3)4 (0.1 equiv)

















aD-AA: D-Orn or D-Lys




Scheme 4.2. Synthesis of DAMGA analogs
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Table 4.6 Analytical data for DAMGA analogs 7-12 
 
 
A 5-50% gradient of MeCN over 45 min at a flowrate of 1 mL / min was used.  
aSystem 1 = 0.1% TFA in aq. MeCN 
bSystem 2 = 0.09 M TEAP and MeCN 
 
      The binding affinities of the DAMGA derivatives 7-12 to MOR and DOR were 
then evaluated in radioligand binding assays as described previously. All of the 
modified analogs 7-12 exhibited subnanomolar affinity for MOR (Table 4.7), 
comparable to that of parent peptide DAMGO, indicating that the C-terminal  
 






a Relative to DAMGO 
Compound 
no. 











7 [D-Orn(=C=S)2]- 19.48/ 100  17.32/ 100 612.3 612.3 
8 [D-Orn(COCH2Br)2]- 12.76 /100  10.22/ 94.9 690.2 690.2, 692.2 
9 [D-Orn(COCH3)2]- 9.49/ 100 7.29/ 100 612.3 612.3 
10 [D-Lys(=C=S)2]- 20.61/ 100 19.02/ 100 626.3 626.3 
11 [D-Lys(COCH2Br)2]- 14.10/ 100 11.77/ 100 704.2 704.2,706.2 
12 [D-Lys(COCH3)2]- 11.29/100  8.82/ 97.1 626.3 626.3 
IC50 









7 [D-Orn(=C=S)2] 0.35 ± 0.05        9.69 ± 0.75 28 1.45 
8 [D-Orn(COCH2Br)] 0.85 ± 0.32       23.4 ± 2.2 27 0.48 
9 [D-Orn(COCH3)2] 0.38 ± 0.13   26.5 ± 2.9 70 1.30 
10 [D-Lys(=C=S)2] 0.57 ± 0.05       74.5 ± 7.6   129 0.89 
11 [D-Lys(COCH2Br)2] 0.45 ± 0.02      30.6 ± 0.7 67 1.10 
12 [D-Lys(COCH3)2] 0.71 ± 0.04      105 ± 11    148 0.72 
DAMGO 0.51 ± 0.01 281 ± 20         550 1.0 
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replacement by the alcohol to amide was well tolerated by MOR. However, most of 
the DAMGA analogs (7-9 and 11) showed considerable affinity for DOR as well, in 
the range of 10-30 nM (Table 4.7). All of the analogs show significantly higher 
affinity for DOR when compared to DAMGO (IC50 = 281 nM). Therefore, the C-
terminal glyol functionality plays an important role in conferring selectivity for MOR 
by decreasing affinity for DOR. The [D-Lys2]DAMGA series of analogs, however, 
showed greater selectivity for MOR compared to the [D-Orn2]DAMGA series of 
analogs. The loss in selectivity for MOR resulting from the replacement of glyol with 
the glycylamide functionality appears to be counterbalanced to some extent by the 
extra methylene unit in the side chain of D-Lys in the case of 10 (IC50 for DOR = 74 



























Figure 4.11. Wash-resistant inhibition of binding by [D-Lys2]DAMGA analogs 10 and 11 
        
      The DAMGA analogs were also evaluated for wash-resistant inhibition of binding 
to MOR according to the established protocol described previously. Among the [D-
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Lys2]DAMGA analogs, as seen in Figure 4.11, the bromoacetamide analog 11 ([D-
Lys(COCH2Br)2]DAMGA) exhibited 44% wash-resistant inhibition of [3H]DAMGO 
binding compared to untreated control membranes. This suggests that this compound 
could be binding irreversibly to MOR and thus be an affinity label. The reversible 
compound, 12, did not exhibit any wash-resistant inhibition of binding, confirming 
the efficiency of the washing procedures in these experiments. The isothiocyanate 
analog, 10, however, was removed from the membrane by the washing procedure 
(>90% [3H]DAMGO binding in presence of 12 at its IC50 concentration, Figure 4.11). 
Although 11 appears to exhibit irreversible binding to MOR at its IC50 value (0.46 
nM), its lower selectivity for MOR over DOR (DOR / MOR = 67, Table 4.7) could be 
an impediment in utilizing 11 as an affinity label for MOR at higher concentrations. 
Wash-resistant inhibition of [3H]DPDPE binding of 11 to DOR needs to be carried 
out to determine whether 11 may interact  irreversibly with DOR. For the [D-
Orn2]DAMGA analogs, in initial wash-resistant inhibition of binding experiments the 
reversible control compound 9 was not removed by the washing procedure, and 
therefore the washing procedure may need to be modified and these experiments will 
need to be repeated. 
4.4 Conclusions 
      A new series of affinity label analogs were successfully prepared using Fmoc-
based solid phase synthesis procedure by replacing the D-Ala2 of DAMGO with 
either D-Orn2 or D-Lys2 and attaching either a bromoacetamide (–COCH2Br) or an 
isothiocyanate (=C=S) as an electrophillic functionality to the side chain amine of 
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either D-Orn2 or D-Lys2. During the purification of both [D-Orn(=C=S)]2DAMGO, 1, 
and [D-Lys(=C=S)2]DAMGO, 4, the formation of an intramolecular cyclic O-alkyl 
thiocarbamate side product occurred. The side reaction was verified by 
characterization of the products obtained from the attempted synthesis of 4 by HPLC, 
MS, FT-IR and NMR. The data obtained from the spectroscopic analysis of the side 
product supports an intramolecular attack of the C-terminal glyol on the 
isothiocyanate in [D-Orn(=C=S)2]DAMGO or [D-Lys(=C=S)2]DAMGO with the 
formation of the cyclic O-alkyl thiocarbamates. The bromoacetamide derivatives (2 
and 5) as well as the reversible controls (3 and 6) were successfully synthesized, 
purified and evaluated for their binding affinities for MOR. The bromoacetamide 
analogs 2 and 5 exhibited subnanomolar binding affinities (IC50 = 0.45 nM) and 
selectivity for MOR over DOR (IC50 ratio 75-230). Interestingly only 2 showed wash-
resistant inhibition of binding (>40% at its IC50 concentration) of [3H]DAMGO to 
MOR while 5 failed to inhibit binding to MOR in a wash-resistant manner, suggesting 
that only 2 binds irreversibly to MOR.  
      The formation of the cyclic O-alkyl thiocarbamate side product from the 
isothiocyanate derivatives was successfully overcome by replacing the C-terminal 
glyol functionality of DAMGO with a glycyl amide. The corresponding DAMGA 
series of affinity labels were successfully synthesized and examined for receptor 
affinity as well as wash-resistant inhibition of binding. The bromoacetamide 
derivative, 11 bound to MOR in a wash resistant manner. However the isothiocyanate 
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analog, 12, failed to demonstrate wash-resistant inhibition of binding at its IC50 
concentration.  
      Although all of the DAMGA analogs exhibited subnanomolar binding affinity 
(IC50 = 0.3-0.8 nM) to MOR in initial radioligand binding experiments, most of the 
DAMGA analogs (7-9 and 11) also had nanomolar affinity for DOR (IC50 = 10-30 
nM). Therefore, the C-terminal glyol functionality plays an important role in 
imparting selectivity for MOR over DOR, and replacing it with a glycylamide 
resulted in significant decreases in MOR selectivity. 
4.5 Experimental 
      The DAMGO-based affinity label analogs were prepared using solid phase 
peptide synthesis methodology described in the previous chapter (Chapter 3, section 
3.7.1). The differences between the two synthetic schemes were in the choice of resin 
and loading of Fmoc-glyol onto the DHP-HM resin.  
Materials 
       The DHP-HM resin (3,4-dihydro-2H-pyran-2ylmethoxymethyl polystyrene, 100-
200 mesh) was obtained from Novabiochem (San Diego, CA). Fmoc-Gly-ol was 
obtained from AnaSpec Inc (Fermont, CA). Pyridinium p-toluenesulfonate (PPTS) 
was obtained from Sigma-Aldrich (Saint Louis, MO). The Fmoc-protected amino 
acids, the remaining chemicals and the HPLC grade solvents were obtained from the 




Synthesis of DAMGO-based analogs 
4.5.1 Loading of Fmoc-Glyol on to DHP-HM Resin and SSPS of DAMGO 
Derivatives (Figure 4.4) 38 
      The first step in the synthesis of the DAMGO-based analogs (Figure 4.3) was 
loading of Fmoc-Gly-ol onto the 3,4-dihydro-2H-pyran-2-ylmethoxymethyl 
polystyrene (DHP-HM) resin (1.3 mmol/ g). The required amount of resin (670 mg) 
was swollen in dichloroethane (DCE, 6 mL) for 1 h. Fmoc-Glyol (740 mg, 3 equiv) 
and PPTS (327 mg, 1.5 equiv) were added to the swollen resin and the mixture stirred 
at 80°C for 48 h. After 48 h the resin was drained, washed with DCM (4 x 1 min), 
DMF (4 x 1 min) and DCM (3 x1 min) and dried under vacuum overnight.  
     The loading of the resin was determined by quantitative analysis of the Fmoc 
group deprotection.40 The deprotection reaction rapidly generates dibenzovulvene, 
which is scavenged by piperidine to afford an adduct that absorbs at 302 nm. The 
resin substitution was calculated according to equation 1 
Substitution in mmol/ g = (A * V * 103)/ 7800 * W                                           (1) 
where A= Absorbance 
            V= Volume (10 mL) 
            W = Weight of the sample resin. 
 
For the Fmoc deprotection and quantitation reaction, three different samples were 
analyzed. These were Fmoc-PAL-PEG-PS resin (3-4 mg) of known substitution (0.38 
mmol/g), a blank and three samples of DHP-HM resin (3-4 mg each) following 
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loading of Fmoc-Glyol as described above. In a 10 mL volumetric flask DCM (0.4 
mL) and piperidine (0.4 mL) were added to the resin and the mixture was kept for 30 
min at room temperature. Then, methanol (1.6 mL) was added to each sample and the 
solutions diluted to 10 mL with DCM. The resulting samples were then filtered and 
the absorbance of each sample recorded at 302 nm.  
      The substitution of DHP-HM resin was determined to be 0.87 mmol/ g following 
this protocol; based on the theoretical substitution (0.95 mmol/ g), and the percent 
loading was 91%. Following determination of the resin loading, ~650 mg of this resin 
was used to synthesize the analogs 1-6 (100 mg for each analog) according to the 
solid phase peptide synthesis procedure described previously (Chapter 3, section 
3.7.1). 
 4.5.2 Solid Phase Peptide Synthesis of the DAMGA Derivatives 
      The synthesis of the DAMGA derivatives (7-12) started with 500 mg of Fmoc-
PAL-PEG-PS (0.38 mmol/g) resin. The Fmoc solid phase peptide synthesis procedure 
described earlier (Chapter 3, section 3.7.1) was used to synthesize all of the analogs. 
4.5.3 Cleavage from Resin 
            The affinity label peptides (1, 2, 4, 5, 7, 8, 10, and 11) were cleaved from 
resin using 95% TFA and 5% water, as described previously in Chapter 3.7.2, and the 
peptides lyophilized to give the crude products. Owing to their lower hydrophobicity, 
the reversible controls (3, 6, 9, and 12) were diluted with 3-4 mL of 10% aqueous 
acetic acid and then back extracted with ether (2 x 2 mL). The aqueous layers were 
collected and lyophilized to give the crude peptides. 
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4.5.4 Purification and Analysis 
      The crude peptides were purified by reversed phase preparative HPLC as 
described in Chapter 3 (section 3.7.3) using a linear gradient of 5-50% aqueous 
MeCN containing 0.1% TFA over 45 min at a flow rate of 20 mL/min. After 
purification of the affinity label analogs (1, 2, 4, 5, 7, 8, 10 and 11) the fractions were 
collected and immediately lyophilized to avoid potential degradation of the affinity 
label analogues by water. The fractions were then analyzed by analytical HPLC and 
ESI-mass spectrometry according to the protocol described in Chapter 3 (section 
3.7.3). For 3, 6, 9 and 12 the pure fractions were then combined and lyophilized to get 
the pure peptide. For 2, 5, 7, 8, 10 and 11 the pure lyophilized fractions were 
combined and re-lyophilized to get the pure peptides. The purity of the final peptides 
were verified in analytical HPLC using two different systems: 0.1% TFA in aq. 
MeCN and 0.09 M TEAP and MeCN 
4.5.5 Instrumentation 
      The FTIR spectra of KBr pellets were collected over a range of 500 to 4000 cm-1 
on a Shimadzu FTIR-8400S spectrophotometer. Proton NMR spectra were recorded 
on a Bruker 500 MHz spectrophotometer in d6 –DMSO. 
4.5.6 Pharmacological Assays:  
      The radioligand binding and wash-resistant inhibition of binding of all of the 
analogs (2, 3, 5, 6 and 7-12) were carried out with Chinese hamster ovary (CHO) 
cells expressing MOR and DOR according to procedures described earlier (Chapter 3, 
 142
section 3.7.4). [3H]DAMGO and [3H]DPDPE were used as the radioligands for MOR 
and DOR, respectively. 
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5.1 Introduction 
      The cloning of the opioid receptors in the early 1990s1-5 led to significant 
advancements in understanding opioid receptor structures and receptor-ligand 
interactions at the molecular level.  
      Affinity labels, ligands that bind to their target receptors in an irreversible 
manner,6 have been useful biochemical tools to study opioid receptors. There have 
been reports in the literature of a large number of affinity labels, mostly nonpeptide 
ligands, for characterizing different opioid receptor types.6, 7 Nonpeptide affinity 
labels for opioid receptors have been predominantly electrophilic affinity labels. β-
Chlornaltrexamine (β-CNA),8 labels all three opioid receptors, and β-funaltrexamine 
(β-FNA) alkylates µ opioid receptors (MOR).9 
      β-FNA, a MOR selective antagonist, was the first affinity label for opioid receptor 
whose point of attachment to its receptor was successfully determined by Liu-Chen 
and coworkers using molecular biology and protein isolation techniques. Initially, 
based on the binding of [3H]β-FNA to MOR / κ opioid receptor (KOR) receptor 
chimeras, a region of MOR spanning from the third intracellular loop to the C-
terminus was determined to be essential for irreversible binding.10 However, upon 
isolation and partial purification of the labeled receptor, the point of attachment was 
found to be in the extracellular loop 2 (EL)-transmembrane 5 (TM5) region. 
Subsequently, site directed mutagenesis of amino acid residues in this region 
identified Lys233, a conserved residues in all three opioid receptors, as the 
attachment point.11 This illustrates the challenges and limitations of studying 
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receptor-ligand interactions and further underscores the importance of obtaining 
direct experimental evidence pertaining to receptor-ligand interactions. The only 
other affinity label whose point of attachment has been determined is the ‘reporter 
affinity label’ naltrexamine naphthalene dialdehyde derivative NNA where the 
attachment points to MOR were evaluated using site-directed mutagenesis by 
Portoghese and coworkers.12 Lys233 and the adjacent Cys235 at the top of TM5 were 
determined to be the residues involved in formation of a fluorescent isoindole with 
NNA indicating covalent binding of the reporter affinity label. Mutation of either of 
these residues resulted in the loss of fluorescence. Although this method allows the 
determination of attachment points without isolating the labeled receptor, a critical 
limitation to this approach is the requirement for two specific nucleophilic receptor 
residues, Lys and Cys, in close proximity to one another to form the fluorescent 
product. 
      Peptide-based affinity labels, on the other hand, have been predominantly 
photoaffinity labels, e.g. the azide derivatives of several enkephalin analogs.6, 7 The 
main disadvantage of using the azido group as a photoaffinity label for opioid 
receptors is that the shorter UV wavelength (254 nm) generally used to generate the 
reactive species can inactivate opioid receptors.13 Reports of peptide-based 
electrophilic affinity labels in literature have been limited. Prior to isothiocyanate 
derivatives of opioid peptides as electrophilic affinity labels designed in our group,14-
16 opioid peptide derivatives containing electrophilic affinity labels were limited to 
chloromethylketone derivatives of the enkephalins,17, 18 the cysteine-containing 
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enkephalin analog of DALCE ([D-Ala2,Leu5Cys6]enkephalin Tyr-D-Ala-Gly-Phe-
Leu-CysOH)19 and enkephalin analogs containing melphanan (Mel),20 the nitrogen 
mustard derivative of p-aminophenylalanine.  
      Since pain relief is mediated mainly through MOR, it is important to understand 
the interactions between MOR ligands and their receptor. The endogenous ligands of 
the opioid receptors are peptides, and studies of chimeric opioid receptors and site-
directed mutagenesis suggest that peptide ligands may interact differently with opioid 
receptors than nonpeptide ligands.21 Therefore, structural information obtained from 
interactions of peptide ligands with opioid receptors can be complimentary to that 
obtained for nonpeptide ligands.  
      There have been very few reports of electrophilic peptide-based affinity labels 
selective for MOR. The chloromethyl ketone of Tyr-D-Ala-Gly-(NMe)Phen (DAMK, 
IC50 = 1-5 µM for dose-dependent irreversible inhibition of [3H]naloxone binding)22 
and Tyr-D-Ala-Gly-Phe-Leu(CH2SNpys) (Npys = 3-nitro-2-pyridinesulphenyl, IC50 = 
19 nM for dose-dependent irreversible inhibition of [3H]DAMGO binding)23  are the 
only examples of peptide-based electrophilic affinity labels for MOR reported in the 
literature. Previous attempts in our group to prepare affinity labels for MOR by 
incorporating an electrophilic functionality such as a bromoacetamide or 
isothiocyanate at the para position of either Phe3 or Phe4 in endomorphin-2 (Tyr-Pro-
Phe-PheNH2) were unsuccessful because the modified analogs exhibited large (40- to 
80-fold) decreases in MOR binding affinity compared to the parent peptide 
endomorphin-2.24 Earlier attempts were also made to identify electrophilic affinity 
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labels based on dermorphin, an endogenous heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-
Pro-SerNH2) derived from South American frog skin that is very potent and highly 
selective for MOR.25 Previously, the para position of Phe3 or a Phe in position 5 of 
dermorphin and [Lys7]dermorphin were modified to introduce an electrophilic 
functionality, i.e. a bromoacetamide or isothiocyanate group.26 Modification in the 
‘message’ domain (Phe3) resulted in a >1000-fold decrease in MOR affinity. While 
modification of a Phe in position 5 in the ‘address’ domain of dermorphin and 
[Lys7]dermorphin was well tolerated and the peptides retained nanomolar affinity for 
MOR, none of these modified analogs exhibited wash-resistant inhibition of binding 
to MOR, and therefore are not affinity labels for these receptors.26 
     In a continued effort to develop MOR selective affinity labels, we have recently 
discovered dermorphin-based affinity label analogs that show exceptionally high 
affinity (IC50 = 0.1-5 nM) for MOR. These analogs were designed by modifying 
position 2 of dermorphin by incorporating D-Orn or D-Lys and attaching a 
bromoacetamide or an isothiocyanate as the electrophilic functionality (see Chapter 3 
for details), which is a new strategy for designing peptide-based affinity label 
derivatives of opioid peptides that has not been previously reported. This resulted in a 
substantial improvement in binding affinity (between 10- to 100-fold) compared to 
the previous dermorphin-based analogs synthesized in our laboratory.26 Importantly, 
three of these four affinity labels, [D-Orn(=C=S)2]-, [D-Orn(-COCH2Br)2]- and [D-
Lys(=C=S)2]dermophin appear to have higher affinity (approximately 3-20 fold) than 
the well-studied nonpeptide MOR affinity label β-FNA (IC50 = 2.2 nM in standard 
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binding assays)10, 27 and exhibit wash-resistant inhibition of binding  at very low (≤ 1 
nM) concentrations equal to their IC50  values.28 To our knowledge, these peptides are the highest 
affinity peptide-based affinity labels for MOR reported to date.  
      The long range goal of this project is to determine the attachment point of a 
peptide-based affinity label to MOR.  In this project, [D-Lys(=C=S)2]dermorphin, one of 
the recently discovered dermorphin-based MOR affinity label (see Chapter 3), was 
selected as the lead peptide for designing a multifunctional probe with the goal of 
identifying the attachment point of this peptide to MOR. This ligand was selected due 
to its high affinity (IC50 = 0.38 nM), selectivity (IC50 ratio DOR/MOR = 250) and its 
ability to bind to MOR in a wash-resistant manner (see Chapter 3). 
      Peptides, due to their polymeric nature, provide definite advantages over 
nonpeptides in isolation studies of affinity labeled receptors. For example, appropriate 
residues in the peptide can be used to attach a purification tag such as biotin or d-
desthiobiotin (DSB). This may then be used to assist in receptor enrichment via 
affinity purification (e.g., with streptavidin for biotinylated peptides). A biotinylated 
derivative of β-endorphin has been used to purify MOR.29 Opioid receptors are 
transmembrane in nature are expressed at very low concentration in different cell 
lines.21 Although MOR has been expressed in Escherichia coli30 and insect cell 
lines,31, 32 the quantities obtained from such expression were not enough to carry out 
spectroscopic studies.33 Affinity purification via d-desthiobiotin-streptavdin 
interaction would enrich the available receptors. The lower affinity of the biotin 
precursor DSB for the biotin binding proteins,34 e.g., streptavidin, compared to biotin 
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offers a distinct advantage over biotin. It is very difficult to dissociate biotinylated 
compounds from streptavidin due to the extremely high affinity of biotin for 
streptavidin (Kd = 4 x 10-14 M),35 which further complicates the analysis of labeled 
receptors. This problem can be overcome by using DSB. Although there is no 
agreement in the literature on how much lower the affinity of DSB is compared to 
biotin, it is believed to be at least several orders of magnitude.36-40 
      To aid in the detection of the labeled receptor in microscopy experiments, a 
fluorescent group incorporated into our lead affinity label peptide [D-
Lys(=C=S)2]dermorphin would be very useful. Previously, fluorescent derivatives 
(Alexa 488 or BIODIPY) attached to either the Lys side chain in  [Lys7]dermorphin41 
or the C-terminus of dermorphin42 have been reported to be well tolerated by MOR. 
Hence, we expect attachment of a fluorescent label to our dermorphin-based affinity 
label peptide will also be well tolerated. To minimize nonspecific interactions with 
the labeled receptor a hydrophilic fluorescent group, i.e. 5-carboxyrhodamine B or 
Oregon Green, was selected. These fluorophores are also insensitive to pH in the 
physiological range43 which minimizes possible alterations of the spectrofluorometric 
properties of the fluorophores with any change in pH (e.g. inside the cell) during 









5.2 Design of a Dermorphin-Based Multifunctional Affinity Label:  
 
Design Strategy  
 
      To develop a multifunctional probe for MOR, the lead peptide [D-
Lys(=C=S)2]dermorphin was further modified to incorporate DSB as a purification 
tag, Oregon Green or 5-carboxyrhodamine B as a fluorescent tag, and poly(ethylene 
glycol) (PEG)-like linkers to decrease the hydrophobicity of the peptide (Figure 5.1). 
Figure 5.2 shows the design of the dermorphin-based multifunctional affinity label 
peptide for MOR. 
 
Figure 5.1. The fluorescent and purification tags and the PEG-like linker for incorporation into 




Figure 5.2. Design of  dermorphin-based multifunctional affinity labels for MOR 
 
The lead peptide [D-Lys(=C=S)2]dermorphin was extended at the C-terminus by two 
additional Lys residues. The Lys residues were separated from each other and the 
peptide by hydrophilic (PEG)-like linkers. The Lys residues were used as handles to 
incorporate the purification and fluorescent tags attached to the side chain amines of 
these residues (Figure 5.2). The fluorescent group was attached to the Lys closest to 
the C-terminus to prevent potential interference with receptor binding. A shorter β-





5.3 Results and Discussion 
5.3.1 Synthesis of the Multifunctional [D-Lys(=C=S)2]dermorphin Derivative 
      A solid phase synthetic methodology was developed to selectively incorporate 
three different labels - a fluorescent label (Oregon Green or 5-carboxyrhodamine B), 
a purification tag (DSB) and the affinity label (isothiocyanate group) into the peptide. 
The choice of the protecting groups for the three different Lys side chain amines in 
the peptide was critical to the success of this strategy. The side chain protecting 
chosen for the synthesis of the multilabeled peptides were Mtt (4-methyltrityl), ivDde 
(1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl) and Aloc 
(allyloxycarbonyl) for the Lys residues from the C- to the N- terminus. The protecting 
groups for the other amino acids remained the same as before (see Chapter 3). The 
structure of the fully protected peptide intermediate on the resin is shown in Figure 
5.3. 
 
Figure 5.3 Structure of the fully protected dermorphin intermediate. 
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Fmoc-PAL-PEG-PS
Fmoc solid phase peptide synthesis
Boc-Tyr-D-Lys-Phe-Gly-Tyr-Pro-Ser-L-Lys-L-Lys- -Ala-NH-PEG-PS
ivDdeAloc
1. 2% hydrazine, DMF
2. DSB/PyBOP/HOBt/DIEA (3:3:3:6) in DMF
3. 3% TFA, DCM
4. Oregon Green
or 5-carboxyrhodamine B/ PyBOP/ HOBt/ DIEA (1:1:1:2)
5. Pd(PPh3)4, PhSiH3 (Aloc deprotection)
tBu
1. Acetic anhydride, DMF
2. 95% TFA, 5% H2O (cleavage)
1.Thiocarbonyldiimidazole, DMF
























X = Oregon Green or
5-carboxyrhodamine B
R = 1 Oregon Green
3 5-carboxyrhodamine B
R







Scheme 5.1 Solid phase synthetic strategy for dermorphin-based multilfunctional peptides. 
      The standard Fmoc solid phase synthetic procedure (Scheme 5.1) was followed to 
assemble the entire peptide chain on the PAL-PEG-PS resin with the side chain 
protecting groups as shown in Figure 5.3. At this stage, ivDde was selectively 
deprotected from the second Lys residue from the C-terminus by treating the peptide 
on the resin with 2% hydrazine44 in the presence of allyl alcohol. Allyl alcohol was 
included in the reaction to prevent reduction of the Aloc group.45 The free amine thus 
generated was then reacted with DSB in the presence of PyBOP and HOBt to 
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incorporate the purification tag. Next the resin was treated with 3% TFA in the 
presence of TIPS (triisopropylsilane) to remove the Mtt group from the Lys residue 
closest to the C-terminus. The free amine thus obtained was then treated with the 
fluorophore Oregon Green 488 5-carboxylic acid to incorporate the fluorescent tag. 
Residual amine groups were acetylated afterwards using acetic anhydride. 
      Since the cost of commercially available single isomer fluorescent dyes is very 
high ($130/ 5 mg for Oregon Green), only one equivalent of this reagent was used for 
incorporation of Oregon Green. Alternatively, 5-carboxyrhodamine B was also used 
as the fluorescent tag. Although the single isomers of carboxyrhodamine are also very 
expensive ($160/10 mg), the sodium salt of a mixture of 5- and 6-carboxyrhodamine 
B is quite inexpensive. It is commercially available as a 20% aqueous solution 
($12.60/kg, Abbey Color, Philadelphia, PA) and is marketed as Rhodamine WT (for 
water tracer).46 Acidic workup of Rhodamine WT with HCl precipitates a mixture of 
the 5- and 6-carboxy isomers which are easily separated by preparative HPLC;46 the 
resulting individual isomers were characterized by analytical HPLC, ESI-MS and 
NMR. However, sample preparation for purification initially met with some 
difficulty, as a mixture of the carboxyrhodamine B isomers was not readily soluble in 
a mixture of MeCN/H2O. After trying different solvents, a 50:50 mixture of 
isopropanol and H2O turned out to be the most suitable solvent; 1 mL of this mixture 
was used to dissolve 40 mg of the sample. Thus, 80 mg of the mixture of 
carboxyrhodamine B isomers could be purified at a time, resulting in ~20 mg of pure  
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Figure 5.4. Separation of 5- and 6-carboxy isomers of rhodamine B in 20-50% MeCN containing 









5-carboxyrhodamine B. 5- and 6-carboxy isomers. The 6-carboxy isomer elutes first 
from the HPLC column, followed by the 5-carboxy isomer as verified by 1H NMR 
spectroscopy. Similar to the coupling of Oregon Green to the multilabeled peptide, 1 
equiv of 5-carboxyrhodamine B was coupled to the free amine side chain of Lys 
obtained after deprotection of the Mtt group with 3% TFA. The reaction was run 
overnight in the dark to prevent possible degradation of the fluorophore in the 
presence of light. Residual amine groups were acetylated afterwards using acetic 
anhydride. The rest of the synthesis was also carried out in the dark for the reason 
described above. After the coupling of 5-carboxyrhodamine B the rest of the 
synthesis (Aloc deprotection and incorporation of the  affinity label) was carried out 
following the established procedures47 (Scheme 5.1). The final cleavage of the crude 
peptides was carried out in 95% TFA and 5% H2O; extraction with ether was avoided 
due to their high hydrophobicities. 
5-carboxyrhodamine B 6-carboxyrhodamine B
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Figure 5.5.  HPLC spectra of the crude multilabeled peptide. A. HPLC after coupling of 5-
carboxyrhodamine and Aloc deprotection. B. Multilabeled peptide 3 after sequential coupling of 5-
carboxyrhodamine, Aloc deprotection and incorporation of the isothiocyanate functionality. A 10-60% 
gradient of aqueous MeCN containing 0.1% TFA over 50 min at a flow rate of 1 mL/min was used for 
HPLC analysis. 
 
      Figure 5.5 shows the HPLC spectra of the crude multilabeled peptide and an 
intermediate. The crude peptides were successfully purified by preparative HPLC; the 
purity of all four peptides 1-4 (>97%) was determined by analytical HPLC in two 






280 nm A 
280 nm B 
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Table 5.1 Analytical data for multilabeled dermorphin analogs 1-4 
 
A 15-50% gradient of MeCN over 35 min at a flowrate of 1 mL/min was used. 
bSystem 2 = 0.09 M TEAP (triethylamine phosphate) and MeCN 
aSystem 1 = 0.1% TFA in aqueous. MeCN 
 
5.3.2 Results from Preliminary Microscopy Experiments 
      To demonstrate possible binding of the multilabeled fluorescent peptide 1 
containing Oregon Green as the fluorophore to MOR, initial microscopic experiments 
were carried out utilizing SH-SY5Y cells, a human neuroblastoma cell line, stably 
expressing MOR and DOR.48 Panel A in Figure 5.6 shows the fluorescence obtained 
after incubating the SH-SY5Y cells with 400 nM of compound 1 for 90 min at 4° C 
followed by extensive washing of the cells. In panel C, the cells were first incubated 
with 400 nM of 1 at 4o C for 90 min followed by incubation with 10 µM of naloxone, 
which is an antagonist with high affinity for MOR,7 for 30 min. The fluorescence due 
to the peptide did not appear to decrease as shown in panel C (Figure 5.6, indicated 











1 [D-Lys(=C=S)2]Oregon Green 21.16/ 100 17.78/ 100 [M+3H]3+ = 703.9 
[M+2H]2+ = 1055.5 
[M+3H]3+ = 703.9 
[M+2H]2+ = 1055.5 
2 [D-Lys(COCH3)2]Oregon Green 15.61/ 97.1 12.92/ 100 [M+3H]3+ = 703.9 
[M+2H]2+ = 1055.5 
[M+3H]3+ = 703.9 
[M+2H]2+ = 1055.5 
3 [D-Lys(=C=S)2]5-carboxyrhodamine 24.87/ 
100.0 
20.91/ 99.8 [M+3H]3+ = 729.0 
[M+2H]2+ = 1093.1 
[M+3H]3+ = 729.0 
[M+2H]2+ = 1093.1 
4 [D-Lys(COCH3)2]5-carboxyrhodamine 19.95/ 97.4 16.17/ 99.0 [M+3H]3+ = 729.0 
[M+2H]2+ = 1093.0 
[M+3H]3+ = 728.7 
[M+2H]2+ = 1093.1
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Figure 5.6. Labeling of SH-SY5Y cells by the [D-Lys(N=C=S)2dermorphin derivative 1 containing 
Oregon Green. A: Labeling of cells with the 400 nM of the fluorescent peptide 1 alone at 4o C for 90 
min (indicated by arrows). B: Protection experiment in which cells were first incubated with naloxone 
(10 µM) for 30 min followed by labeling with 1 at 4o C for 90 min. C: Labeling of cells with the 
peptide (indicated by arrows) for 90 min, followed by incubation with naloxone. D: Cells not 
incubated with peptide or naloxone for 90 min. Cells were extensively washed following incubation. 




  C   D 
  A   B 
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MOR and suggesting that the peptide may bind irreversibly to MOR. To verify 
whether the fluorescent peptide 1 and naloxone are interacting with the same 
receptor, a protection experiment was carried out, where cells were first treated with 
10 µM of naloxone for 30 min followed by a treatment with 400 nM of 1 for 90 min. 
As can be seen in panel B of Figure 5.6 minimal fluorescence above background was 
observed consistent with peptide 1 and naloxone interacting with the same receptor. 
To detect any auto-fluorescence of the SH-SY5Y cells in the labeling experiments, 
cells were treated with buffer only (panel D of Figure 5.6). Therefore the results 
obtained from this preliminary microscopy experiment suggest labeling of MOR by 
the dermorphin-based multifunctional peptide 1. The inability of naloxone to displace 
the fluorescent peptide from MOR further suggests that the peptide binds irreversibly 
to MOR, and thus demonstrates the utility of this approach. 
5.4. Conclusions 
      A multifunctional affinity label peptide was designed by modifying [D-
Lys(=C=S)2]dermorphin which exhibits high affinity (IC50 = 0.38 nM), selectivity 
and wash resistant inhibition of binding to MOR (Chapter 3). The design involved 
incorporating additional C-terminal Lys residues as handles to attach a purification 
tag and fluorescent tags to aid in receptor isolation and detection of the labeled 
receptor, respectively. A solid-phase synthetic methodology utilizing selective 
deprotection of different protecting groups on the side chain amines of Lys residues 
permitted the incorporation of multiple labels (Oregon Green or 5-carboxyrhodamine 
B and DSB) to yield the multilabeled dermorphin derivatives. Preliminary 
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microscopy experiments examining the interaction of the fluorescent peptide 1 with 
MOR on SH-SY5Y cells suggests irreversible binding of the multifunctional affinity 
label dermorphin derivative, and thus demonstrates the utility of this approach. 
Radioligand binding assays of 1-4 will be carried out in the near future to determine 
the affinity and confirm the wash-resistant inhibition of binding of the multilabeled 
[D-Lys(=C=S)2]dermorphin derivatives. Additional microscopic experiments will 
also be performed to verify the results of the initial studies, to evaluate the effects of 




5.5.1 Synthesis of Dermorphin-based Multifunctional Affinity Label   
      The dermorphin-based multifunctional affinity label derivatives were prepared by 
solid phase peptide synthesis methodology described in Chapter 3. The methodology 
for selective incorporation of different functional tags (purification and fluorescent 
tags) is described below. 
 
Materials 
The Fmoc-mini-PEG linker (2-(2-(2-aminoethoxy)ethoxy)acetic acid) was purchased 
from Peptides International (Louisville, KY). Fmoc-βAla-OH, Fmoc-Lys(Mtt)-OH 
and Fmoc-Lys(ivDde)-OH were purchased from Novabiochem (San Diego, CA). 
Oregon Green 488, Rhodamine WT and d-desthiobiotin were obtained from 
Molecular Probes (Eugene, OR), Abbey Color (Philadelphia, PA) and Sigma-Aldrich 
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(St. Louis, MO), respectively. Hydrazine was obtained from Sigma-Aldrich (St. 
Louis, MO). The remaining chemicals, Fmoc protected amino acids, Fmoc-PAL-
PEG-PS resin, and HPLC grade solvents were obtained from sources listed in Chapter 
3. 
Synthesis of dermorphin-based multifunctional affinity labels 
In addition to the Fmoc-protected amino acids mentioned in Chapter 3, Fmoc-βAla-
OH, Fmoc-Lys(Mtt)-OH, Fmoc-mini-PEG-linker and Fmoc-Lys(ivDde)-OH were 
used in the synthesis. The synthesis started with Fmoc-PAL-PEG-PS resin (300 mg, 
0.19–0.21 mmol/g). Following Fmoc deprotection of the resin using piperidine and 
DMF (1:4), Fmoc-βAla-OH, Fmoc-Lys(Mtt)-OH, Fmoc-mini-PEG-linker and Fmoc-
Lys(ivDde)-OH were sequentially coupled following the Fmoc solid phase peptide 
synthesis procedures described in Chapter 3 (Scheme 5.1). The peptide chain was 
then further elongated with Fmoc-mini-PEG-linker and the fully protected 
dermorphin peptide sequence assembled on the resin as per the protocol in Chapter 3. 
The linkers, Ser7, Pro6 and the N-terminal Tyr1 were coupled twice and required 
overnight reaction for the second coupling. The completion of the couplings of amino 
acids and linker were monitored by the ninhydrin test for coupling to a primary amine 
and by the chloranil test if coupled to a secondary amine. 
      After assembly of the entire peptide chain on the resin, the ivDde protecting group 
from the C-terminal Lys was selectively removed by treatment with 2% hydrazine in 
DMF twice for 10 min. The resin was then washed with DCM/DMF (1:1, 10 x 1 
min). DSB was then coupled to the resulting primary amine with PyBOP, and HOBt 
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as the coupling agents and DIEA as base. DSB (3 equiv) was first dissolved in a 
minimum amount of DMSO: DMF (1:1). PyBOP (3 equiv) and HOBt (3 equiv) were 
dissolved in a a minimum amount of DMSO: DMF (1:1) separately and the solution 
then added to the DSB followed by DIEA (6 equiv). The mixture was then added to 
the resin and the reaction run overnight. The completion of the coupling was verified 
by a negative ninhydrin test. Next the Mtt group from the second Lys from the C-
terminus was selectively deprotected by treatment with 3% TFA and 1% TIPS in 
DCM for 30 mins.  The resin was then washed with DCM/DMF (1:1, 10 x 1 min). 
The resultant free amine was reacted with Oregon Green 488, PyBOP, HOBt and 
DIEA (1:1:1:2) overnight in the dark. Residual amine groups were acetylated 
afterwards using acetic anhydride. Cleavage of an aliquot (~15 mg) and analysis by 
HPLC and ESI-MS were carried out to verify the product. At this stage, the Aloc 
group of the side chain of D-Lys2 was deprotected with a catalytic amount of 
Pd(PPh3)4 plus phenyl silane according to the procedure described previously.47, 49 
The resin containing the free amine on the side chain of D-Lys2 was then divided into 
two parts (100 mg each). One part was treated with a large excess of acetic anhydride 
(20 equiv) in DMF to obtain the acetylated control compound. The second part was 
reacted with thiocarbonyl diimidazole (4 equiv) in DMF to yield the desired 
isothiocyanate affinity label as per the protocol described earlier in Chapter 3.  
      To synthesize the dermorphin-based multifuctional affinity label containing 5-
carboxyrhodamine B, the 5-isomer was isolated from the mixture of the two isomers 
(5- and 6-carboxyrhodamine B) in Rhodamine WT (see section 5.5.4 below). The 
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peptide was synthesized following the same procedure described above. Aliquot 
analysis by HPLC (Figure 5.5) and ESI-MS was carried out after reaction of 5-
carboxyrhodamine B as described above to verify the product. Aloc deprotection and 
subsequent synthesis of the reversible control and affinity label were carried out 
following the protocol described above.  
      It is important to note that all synthetic steps following incorporation of the 
fluorescent functionalities Oregon Green or 5-carboxyrhodamine B were carried out 
in the dark to prevent possible degradation of the fluorophore. 
5.5.2 Cleavage from Resin 
      The peptides were cleaved from the resin with 95% TFA and 5% H2O for 2 h in 
the dark. Due to the considerable hydrophobicties of these peptides ether extraction 
was not carried out. Instead, following filtration of the resin excess TFA was removed 
by evaporation. The resulting peptide was diluted 10 fold with 10% aqueous acetic 
acid and lyophilized to get the crude products.  
5.5.3 Purification and Analysis 
     The crude peptides (1-4, 30-40 mg each) were purified by reversed phase 
preparative HPLC as described in chapter 3 using a linear gradient of 15-70% 
aqueous MeCN containing 0.1% TFA over 55 min at a flow rate of 20 mL/min. The 
samples were prepared by dissolving the crude peptides in 1:9 MeCN: H2O. After 
purification of the affinity label analogs (1 and 3) the fractions were collected and 
immediately lyophilized to avoid potential degradation of the affinity label. The 
fractions were then analyzed by analytical HPLC and ESI-mass spectrometry 
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according to the protocol described in chapter 3 (section 3.5.3). For the affinity labels 
1 and 3 the pure lyophilized fractions were dissolved, combined and re-lyophilized to 
give the pure peptides. For the reversible control peptides 2 and 4, the pure fractions 
were combined and lyophilized to give the pure peptides. The purity of the final 
peptides (1-4) was verified by analytical HPLC using two different solvent systems: 
0.1% TFA in aqueous MeCN and 0.09 M TEAP (triethylamine phosphate) and 
MeCN (see Table 5.1). 
5.5.4 Separation of the Isomers from Rhodamine WT. 
     Rhodamine WT (Abby Color) was obtained as the sodium salt as a 20% aqueous 
solution. Acidification of Rhodamine WT (25 mL) by dropwise addition of 2 equiv of 
3 M HCl precipitated a mixture of the 5- and 6-carboxy isomers. The precipitate was 
lyophilized after adding a few mL of water to give the crude product. The retention 
times of the two isomers were 19.01 and 25.37 min by analytical HPLC (20-50% 
gradient of aq MeCN containing 0.1% TFA over 60 min). For purification of 5-
carboxyrhodamine B from the mixture, 40 mg of the crude sample was dissolved per 
mL of isopropanol/water in the ration of 1:1. The solution was then sonicated and 
centrifuged for 10 min. The purification was carried out by reversed phase 
preparative HPLC using 25-55% aqueous MeCN (containing 0.1% TFA) over 60 
min. The fractions for the two isomers were collected separately, lyophilized and 
analyzed by HPLC and ESI-MS. The identities of the isomers were determined using 
proton NMR analysis in deuterated methanol of each pure isomer. The chemical 
shifts (ppm) of the protons shown in Figure 5.7 for the two isomers of 
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carboxyrhodamine B are as follows: for 5-carboxyrhodamine B, the chemical shifts 
were δ 8.63 (H1), δ 8.32 (H2), δ 7.54 (H3) and for 6-carboxyrhodamine B, the 
chemical shifts were δ 7.18 (H1), δ 7.15 (H2) and δ 6.73 (H3).50 Based on the NMR, 
the peaks from HPLC were assigned as 6-carboxyrhodamine (tR = 19.01 min) and 5-
carboxyrhodamine B (tR = 25.37 min). From 80 mgs of crude Rhodamine B, 20 mg of 
pure 5-carboxyrhodamine B was 
  
 
Figure 5.7. Isomers of carboxyrhodamine B 
 
obtained. The purity of 5-carboxyrhodamine B was verified by analytical HPLC using 
two different solvent systems: 0.1% TFA in aqueous MeCN (20-50% over 30 min, tR 
= 11.92 min, purity = 97.8%) and 0.1% TFA in aqueous MeOH (tR = 23.25 min, 
purity = 98.6%). The molecular weight of 5-carboxyrhodamine B was verified by 
ESI-MS mass spectroscopy (m/z = 487.88 for [M+H]+1) using a Waters LCT Premier 




5.5.5 Microscopy Experiments 
     SH-SY5Y cells stably expressing MOR and DOR were purchased from ATCC 
(American Type Culture Collection). SH-SY5Y cells were seeded onto a 384 well 
plate in phenol-free RPMI media containing 10% FBS (fetal bovine serum) and high 
glucose (4500 mg/L), and the cells incubated for 36 hours. Following incubation, the 
cells were washed with PBS (phosphate buffered saline) and the plate was centrifuged 
for 5 min at 1000 rpm using a Sorvall centrifuge to make certain that the SH-SY5Y 
cells were attached to the plate surface. 
      After centrifugation, a group of cells was treated with the affinity label (1) (400 
nM) for 90 min at 4° C. For protection experiments, another group of cells was first 
treated with naloxone (10 µM) for 30 min at 4° C followed by treatment with 1 (400 
nM) for 90 minutes at 4° C. A third group of cells was treated with 1 for 90 min at 4o 
C followed by naloxone incubation (10 µM) for 30 min at 4° C, and finally a fourth 
group of cells was treated with only PBS for 90 min at 4° C. Following all of the 
treatments, all groups of cells were washed with ice-cold PBS 5 times and the plate 
was kept on ice until microscopy was performed. 
       Images of each group of cells were then taken by epifluorescence microscopy 
using 494 nm as the excitation wavelength and 531 nm as the emission wavelength 
appropriate for Oregon Green. Imaging was performed on a custom-built spinning 
disk confocol microscope (Intelligent Imaging Innovations, Denver CO, CSU-10-
Based) using an Olympus IX-81 inverted fluorescence microscope frame laser 
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appropriate for excitation of Oregon Green. Cells were imaged using a Hamamatsu 
Back-Thinned EMCCD (512 x 512) for epifluoroscence using an appropriately 
matched emission filter and a high speed (<8 ms) emission filter wheel.  
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      The objective of this dissertation work was to design, and synthesize peptide-
based affinity labels for µ opioid receptors (MOR). Affinity labels, compounds that 
bind to their target receptor in an irreversible manner, can be very useful tools to 
study receptor-ligand interactions.1 Since the endogenous ligands for opioid receptors 
are peptides, information obtained from such peptide-based affinity labels could 
provide valuable insights that can facilitate the development of novel therapeutic 
agents. 
      Towards this goal, dermorphin and DAMGO were selected as parent peptides in 
this research for developing affinity labels, including multifunctional affinity labels, 
for MOR. The methodology, synthesis and results obtained from these studies have 
been described in detail in Chapters 3, 4 and 5. Here the important conclusions and 
significance of the projects will be summarized and future work described.  
6.2 Conclusions from Research Projects  
6.2.1 Project 1 
Discovery of Dermorphin-Based Affinity Labels with Subnanomolar Affinity for 
Mu Opioid Receptors (Chapter 3) 
      A series of affinity label analogs with high affinity and selectivity for MOR were 
discovered by substituting D-Ala2 of dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-
SerNH2) with either D-Orn2 or D-Lys2 and attaching either an isothiocyanate or a 
bromoacetamide onto the side chain amine of these two modified analogs.2, 3  All four 
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potential affinity label derivatives exhibited very high affinity (0.1-5 nM, Table 6.1) 
for MOR in standard radioligand binding assays. This was a substantial improvement 
in binding affinity (between 10- to 100-fold) compared to the previous dermorphin-
based analogs synthesized in our laboratory in which the para position of Phe3 or a 
Phe in position 5 of dermorphin or [Lys7]dermorphin were modified.4 Futhermore, 
three of these four potential affinity labels showed subnanomolar binding affinity 
(IC50 < 1 nM) indicating that these modifications are well tolerated in the binding 
pocket of MOR. From the differences in the binding affinities observed in the case of 
the bromoacetamide derivatives in the D-Orn vs. D-Lys series of derivatives (Table 
6.1), it appears that the different lengths of the side chains in D-Lys and D-Orn as 
well as the identity of the attached functionality play important roles in determining 
the affinities of these dermorphin analogs for MOR.  
Table 6.1: Binding affinities of dermorphin derivatives for MOR and DOR 
 





IC50 ratio Dermorphin Analogs 
MOR DOR  DOR/MOR 
1 [D-Orn(=C=S)2] 0.81 ± 0.29 23.8 ±2.1 0.89 29 
2 [D-Orn(COCH2Br)2] 0.11 ± 0.02 342 ± 20 6.54 3110 
3 [D-Orn(COCH3)2] 4.25 ± 0.35 272 ± 23 0.17 64 
4 [D-Lys(=C=S)2] 0.38 ± 0.08 97.1 ±4.9 1.89 255 
5 [D-Lys(COCH2Br)2] 5.23 ± 2.31 382 ± 22 0.14 73 
6 [D-Lys(COCH3)2] 29.8 ± 7.6 436 ± 34 0.02 15 
Dermorphinb 0.72 ± 0.07 197 ± 28 1.0 274 
a Relative to dermorphin. b From ref. 4. 
 
      In the wash-resistant inhibition of binding experiments, all four potential affinity 
labels exhibit 30-40 % inhibition of [3H]DAMGO in a wash-resistant manner, three 
of them (1, 4 and 5) at concentrations equal to their IC50 values. One analog, 2, 
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required higher concentration (1 nM) than its IC50 value (0.11 nM) to exhibit wash-
resistant inhibition of binding to MOR. These results indicate these four modified 
analogs of dermorphin are electrophilic affinity labels that likely bind irreversibly to 
MOR. In addition, analogs 2 and 4 also exhibited concentration-dependent wash 
resistant inhibition of binding when evaluated at concentrations higher than their IC50 
values. 
      To the best of our knowledge, the peptide-based affinity labels discovered in the 
present study have the highest binding affinity for MOR among the peptide-based 
affinity labels reported in the literature. These peptides exhibit 4- to 190-fold higher 
affinity compared to the Tyr-D-Ala-Gly-Phe-Leu(CH2SNpys), reported to date to 
have the highest affinity for MOR (IC50 = 19 nM in standard radioligand binding 
assays).5  
6.2.2 Project 2 
Synthesis and Evaluation of DAMGO-Based Affinity Labels for MOR and 
Discovery of an Unexpected Side Reaction (Chapter 4) 
      The objective of this project was to design, synthesize and evaluate DAMGO 
(Tyr-D-Ala-Gly-MePhe-Gly-ol)-based affinity labels for MOR. With the successful 
discovery of dermorphin-based affinity labels described above (Project 1), the same 
design strategy was applied to prepare DAMGO-based affinity labels. This would 
serve two purposes: 1) To establish whether this design strategy, i.e. attachment of an 
affinity label group to the side chain amine of a D-amino acid (e.g. D-Orn or D-Lys) 
at the  2nd position of these peptide ligands, could be a general approach for 
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generating affinity label derivatives of opioid peptides, and 2) from the binding data, 
to examine whether this residue may bind similarly to MOR when incorporated in  
peptides with different message sequences, i.e Tyr-X-Gly-Phe (X = D-amino acid) 
present in frog skin peptides e.g. dermorphin,6 and  DAMGO, a synthetic analog of 
enkephalin,7 with the Tyr-Gly-Gly-Phe sequence present in endogenous mammalian 
opioid peptides.8 
      Of the four affinity labels (7, 8, 10, and 11), two (8 and 11) showed exceptionally 
high binding affinity and moderate selectivity for MOR (Table 6.2). Of these two, 
only 8 exhibited significant (>40%) wash-resistant inhibition of binding of 
[3H]DAMGO to MOR at a concentration equal to its IC50 value, suggesting possible 
irreversible binding of 8 to MOR. Analog 11, on the other hand, did not remain in the 
receptor membrane after the washing procedure. Interestingly purification and  









a Relative to DAMGO, b Side reaction 
 
IC50 







DAMGO  Analogs MOR DOR DOR/MOR  
7 [D-Orn(=C=S)2] b 
8 [D-Orn(COCH2Br)2] 0.45 ± 0.06    33.1 ± 0.9 73 1.1 
9 [D-Orn(COCH3)2]  0.58 ± 0.11 102 ± 6 176  0.88 
10 [D-Lys(=C=S)2] b 
11 [D-Lys(COCH2Br)2] 0.45 ± 0.25    103 ± 1 229 1.1 
12 [D-Lys(COCH3)2] 1.13 ± 0.22    268 ± 28 237 0.45 
DAMGA Analogs     
13 [D-Orn(=C=S)2] 0.35 ± 0.05     9.69 ± 0.75 28 1.46 
14 [D-Orn(COCH2Br)] 0.85 ± 0.37    23.4 ± 2.2 26 0.60 
15 [D-Orn(COCH3)2] 0.38 ± 0.13 26.5 ± 2.9 70 1.34 
16 [D-Lys(=C=S)2] 0.57 ± 0.05    74.5 ± 7.6  129 0.89 
17 [D-Lys(COCH2Br)2] 0.45 ± 0.02    30.6 ± 0.7  67 1.13 
18 [D-Lys(COCH3)2] 0.71 ± 0.04    105 ± 11   148 0.72 
DAMGO 0.51 ± 0.01 281 ± 20 550 1.0 
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analysis of the isothiocyanate-containing analogs (7 and 10) revealed an unexpected 
side reaction with the formation of cyclic O-alkyl thiocarbamates. This side reaction 
involves the C-terminal gly-ol functionality of DAMGO acting as a nucleophile and 
attacking the electrophilic isothiocyanate functionality attached to the side chain of 
either D-Orn or D-Lys. This leads to the formation of the cyclic O-alkyl 













































Figure 6.1. Cyclization reaction leading to the cyclic O-alkyl thiocarbamate side product. Reaction of 
[D-Lys(=C=S)2]DAMGO is shown as the example. 
 
      The design of the affinity label derivatives was then modified to overcome the 
formation of this side product by replacing the C-terminal glyol group by a 
glycylamide functionality to give [D-Ala2,NMePhe4,Gly5]enkephalinamide 
(DAMGA). The new series of analogs (13-18, Table 6.2) containing the 
isothiocyanate and bromoacetamide functionalities were then successfully prepared 
and evaluated for their binding affinities to MOR. As shown in Table 6.2, although 
the new series of analogs maintain extremely high affinity (IC50 = 0.3-0.8 nM) for 
MOR, the selectivity of most of these ligands for MOR dropped significantly (3- to 4-
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fold) compared to the DAMGO derivatives. This suggests that the C-terminal glyol 
functionality plays an important role in conferring selectivity for MOR, as replacing it 
with the glycylamide functionality resulted in increased affinity for DOR. 
      The present study successfully established a general approach for designing 
affinity labels based on MOR-selective peptide ligands containing a D-amino acid at 
position 2. The modifications were well tolerated and the resulting peptides showed 
very high affinity for MOR. One of the DAMGO-based analogs, 8, showed >40% 
wash-resistant inhibition of binding of [3H]DAMGO to MOR at concentration equal 
to its IC50 value (0.45 nM), suggesting irreversible binding of this analog to MOR. Of 
the [D-Lys2]DAMGA series of analogs (16 – 18), 17 exhibited 44% wash-resistant 
inhibition of binding at concentration equal to its IC50 value suggesting this peptide 
may interact irreversibly with MOR. The wash-resistant inhibition of binding of [D-
Orn2]DAMGA derivatives (13 – 15) will be carried out soon. 
6.2.3 Project 3 
Design, Synthesis and Evaluation of a Dermorphin-Based Multifunctional 
Affinity Label Probe for Mu Opioid Receptors (Chapter 5) 
      With the long range goal of identifying the point of attachment of a peptide-based 
affinity label to MOR, the objective of this project was to design and synthesize a 
MOR selective affinity label peptide as a multifunctional probe which would 
facilitate the process of receptor isolation and identification of the attachment point of 
the affinity label to MOR. 
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      Towards this goal, a MOR-selective peptide-based affinity label [D-
Lys(=C=S)2]dermorphin (Project 1, Chapter 3, compound 4) was chosen as the lead 
peptide for incorporating additional functionalities, namely d-desthiobiotin (DSB) as 
a purification tag, and Oregon Green or 5-carboxyrhodamine B as a fluorescent tag 
(Figure 6.2) to facilitate receptor isolation and aid in visualizing the labeled receptor, 
respectively. This particular analog was chosen due to its high binding affinity (IC50 = 























































X= =C=S (affinity label)
= -COCH3 (reversible control) PEG-like Linkers
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Figure 6.2. The design of the dermorphin-based multifunctional affinity label for MOR 
 
MOR in a concentration-dependent manner (see Chapter 3). The design of this 
multifunctional affinity label probe included additional Lys residues that served as 
handles to incorporate the additional tags. The purification tag and the fluorescent tag 
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were separated from each other and from the peptide by a hydrophilic poly(ethylene 
glycol) (PEG)-like linker to increase the water solubility of the peptide and decrease 
nonspecific binding. 
      The synthetic methodology to prepare this multifunctional affinity label peptide 
on a solid support involved choosing protecting groups for the three different Lys side 
chain amines present in the multilabel peptide so that each protecting group could be 
selectively removed and the appropriate label incorporated without affecting the other 
protecting groups present in this peptide. Employing this synthetic strategy the 
multilabeled analogs were successfully synthesized and obtained in >97% purity 
based on analytical HPLC following purification. 
      With the successful synthesis of the multifunctional affinity label peptides, 
preliminary microscopic experiments were performed by labeling SH-SY5Y cells that 
stably express MOR with the multilabeled [D-Lys(=C=S)2]dermorphin derivative 
containing Oregon Green (Compound 1, Chapter 5). Preliminary microscopic results 
obtained by labeling SH-SY5Y cells with 1, including protection and displacement 
experiments with the MOR antagonist naloxone, suggest irreversible binding of 1 to 
MOR. Thus, the multifunctional probe was successfully used to label and visualize 
MOR, demonstrating the utility of this approach. 
6.3 Future Work 
      The multilabeled affinity label peptide containing Oregon Green or 5-
carboxyrhodamine B will first be evaluated for MOR affinity and selectivity in 
standard radioligand binding assays using CHO cells stably expressing MOR and 
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DOR to determine their affinities relative to parent affinity label derivative of 
dermorphin (compound 4, Chapter 3). The wash-resistant inhibition of binding by the 
multifunctional peptides (compound 1 and 3, Chapter 5) will be examined to optimize 
concentration, and incubation time.10 To ensure effective removal of noncovalently 
bound compound and to assess efficiency of the washing procedure, reversible 
control multilabeled peptides (2 and 4, Chapter 5) will also be evaluated for wash-
resistant inhibition of binding. Optimizing the washing procedure is particularly 
important since addition of DSB and fluorescent group could make difficult to 
remove noncovalently bound peptide from MOR. 
      The microscopy experiments with the multifunctional peptide described in 
Chapter 5 will be repeated using CHO cells expressing MOR. Wash-resistant 
fluorescent labeling of cells with the peptides 1 and 3 (Chapter 5) will be evaluated 
using confocal microscopy. Like the wash-resistant inhibition of binding assay, 
parallel experiments will also be performed with the reversible control compounds (2 
and 4, Chapter 5) to evaluate the effectiveness of the washing procedure. 
      The long range goal of this project is to identify the attachment point of the 
peptide-based affinity label to MOR. After the binding affinities are determined in 
radioligand binding assays and wash-resistant inhibition of binding and wash-
resistant fluorescent labeling evaluated as described above, receptor isolation studies 
will be undertaken to determine the attachment point of the multifunctional peptide to 
MOR. The CHO cells stably expressing MOR will be labeled with the fluorescent 
peptide at an appropriate concentration. Epitope tagged MOR will be used for such 
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isolation experiments and immunoprecipitation of the labeled receptor using an 
appropriate antibody against the epitope will also be included in the isolation 
procedure. Since the peptide contains a fluorescent label, SDS-PAGE of the labeled 
receptor followed by fluorescent imaging would help identify the desired band. The 
labeled receptor band thus isolated could then be enzymatically cleaved and the 
labeled receptor fragment could be further isolated from other unlabeled fragments 
through binding of the DSB group to streptavidin11 and the unlabeled fragments 
removed by washing. The isolated labeled fragments will then be analyzed by 
MALDI-TOF-MS (matrix-assisted laser desorption/ionization-time of flight-mass 
spectrometry) to attempt to determine the attachment point.11-13 The optimum 
conditions (compatibility with detergents, concentration, incubation time, elution 
efficiency from the streptavidin bound peptides, etc) will be first established based on 
detailed model studies with the multilabeled peptides based on literature procedures 
used in the purification of MOR.14 For these studies deuterated multilabeled peptides 
would be prepared to assist detection labeled fragments by MALDI-TOF-MS.15 
      Another important application of the multilabeled fluorescent peptide will be to 
study receptor internalization. After labeling MOR expressed on CHO cells with 
dermorphin-based fluorescent peptides at a low temperature (4° C), internalization 
can be monitored by confocol microscopy following raising the temperature to 35° 
C.16 Since dermorphin is an agonist, the multilabeled derivative would be expected to 
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